Supplement 2 2025
Differences between physical medicine and rehabilitation and other clinical branches in terms of dual-energy X-ray absorbsiyometri (DEXA)-related data
Veysel Delen 1, Ferit Dogan 2
1 Department of Physical Medicine and Rehabilitation, 2 Department of Radiology, Faculty of Medicine, Harran University, Sanlıurfa, Turkiye
DOI: 10.4328/ACAM.22362 Received: 2024-08-07 Accepted: 2024-09-09 Published Online: 2024-11-26 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S91-94
Corresponding Author: Veysel Delen, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Harran University, Sanlıurfa, Turkiye. E-mail: veyseldelen@gmail.com P: +90 414 318 30 27 Corresponding Author ORCID ID: https://orcid.org/0000-0002-8152-4628
Other Authors ORCID ID: Ferit Dogan, https://orcid.org/0000-0001-9507-6670
This study was approved by the Ethics Committee of Harran University (Date: 2024-07-22, No: HRÜ/24.10.56)
Aim: This study aimed to focus on the differences of physical medicine and rehabilitation (PMR) than other clinical branches in terms of Dual-Energy X-Ray Absorbsiyometri (DEXA)-related data.
Material and Methods: A total of 1293 patients from the five clinical branches that most frequently requested DEXA [the PMR, Orthopedics and Traumatology (OT), Gynecology and Obstetrics (GO) Endocrinology (END), Neurology (NEU)] and their DEXA-related data were investigated retrospectively. The DEXA-related data of PMR were compared statistically with other clinical branches.
Results: Considering age, OT was similar to PMR, while END, GO, and NEU were lower than PMR. Considering gender (F/M), OT and END were similar to PMR, while GO was higher, and NEU was lower than PMR. Considering BMD, while OT was higher, END and NEU were lower than PMR, GO was similar to PMR. Considering osteoporosis frequency at lumbar spine, while OT and GO were lower than PMR, END and NEU were similar to PMR. Considering osteoporosis frequency at femur neck, OT, END, and GO were similar to PMR, while NEU was lower than PMR.
Discussion: The differences in DEXA-related data seen between PMR and other clinical branches may be due to differences in patient profiles.
Keywords: Osteoporosis, Physical Medicine, Orthopedics, Endocrinology, Neurology
Introduction
Osteoporosis is an important and common bone disease causing notable economic costs globally. It is characterised by decreases in quality, turnover, strength, and mass of bone resulting an increased risk of life-threating fractures [1]. Traditional pathophysiology of osteoporosis is associated with deficiencies in estrogen, vitamin D, and calcium leading to osteoclastic activation and osteoblastic inhibition resulting in bone resorbtion [1, 2]. On the other hand, current pathophysiology of osteoporosis includes multifactorial mechanisms such as osteoimmunological, gut microbiome or gastrointestinal factors, cellular senescence or age-related bone loss, and genetically tendency [1- 4]. Osteoporosis necessitates early diagnostic and therapeutic management to protect bone health [5].
Dual-energy X-ray absorptiometry (DEXA), which measures and compares bone mineral density (BMD) to age-based standards, is the gold standard tool used to diagnose osteoporosis [5]. It has been reported that using DEXA to screen individuals ≥50 years old for osteoporosis reduces osteoporosis-related fracture, mortality, and costs [6]. According to the WHO diagnostic classification including DEXA results, osteoporosis is defined by T-score, which is an indicator of BMD, at the hip or lumbar spine equal to or less than -2.5 standard deviations relative to the mean T-score of the young adult reference population. Normal BMD is defined as a T-score of -1.0 or higher. If BMD is a T-score between -1.0 and -2.5, it is defined as osteopenia or low bone mass [7].
Although the patient profiles encountered by different clinical branches are also different, osteoporosis may be found in patients applying to any clinical department. For example, the Orthopedics and Traumatology (OT) department encounters more patients with fractures and can investigate the relation between fracture and osteoporosis. The Department of Gynecology and Obstetrics (GO) often evaluates postmenopausal women and can also investigate these patients for osteoporosis. The Endocrinology (END) department can evaluate patients in terms of the risk of osteoporosis caused by hormonal disorders. The Neurology (NEU) department may take into account the increased risk of osteoporosis due to the elderly population and the immobile patient group it encounters. Therefore, in addition to physical medicine and rehabilitation (PMR), which is the clinical branch primarily related to the musculoskeletal system, other clinical branches may also request DEXA to evaluate the patient for osteoporosis. However, it is not known that the differences between PMR and other clinical branches in terms of DEXA-related data. Therefore, the present study aimed to focus on the differences of PMR than other clinical branches in terms of DEXA-related data.
Material and Methods
This was a retrospective comparative study focused on the differences between PMR and other clinical branches in terms of DEXA-related data. The data were obtained from the Hospital’s information systems between January 1, 2022 and January 1, 2023. In accordance with the comments of the Declaration of Helsinki, the study was planned, performed and completed.
The BMD measurement was performed using the Hologic QDR 4500 DXA scanner device (Hologic, Bedford, MA, USA). Measurements included the lumbar spine and femoral neck.
The inclusion and exclusion criteria were as follows: During the determined one-year period, all DEXA requested from all clinical branches were included in the study. Patients aged 18-65 years were selected to collect a study population. On the other hand, patients with inadequate data, aged <18 or >64 years were excluded.
A total of 1293 patients from the five clinical branches that most frequently requested DEXA and their DEXA-related data were investigated retrospectively. The DEXA-related data of PMR were compared statistically with other clinical branches.
Statistical analysis
The statistical analyses were done by using IBM SPSS Statistics version 27.0. The Kolmogorov-Smirnov test was applied to continuous variables to test normality assumption. All of the continuous variables (age, weight, height, BMI, lumbar spine T score, and femur neck T score) in the PMR group exhibited a non-normal distribution. Therefore, the Mann-Whitney U test was used in the statistical comparisons between PMR and other groups for continuous variables. Continuous data were presented as mean±SD (min.-max.). Categorical variables were evaluated by the Fisher’s exact test and were presented as number (percentage). Statistically significant level was considered as p<0.05.
Ethical Approval
This study was approved by the Ethics Committee of Harran University (Date: 2024-07-22, No: HRÜ/24.10.56).
Results
The branches and the DEXA numbers they requested during the specified one-year period were as follows: PMR (n=721), OT (n=369), END (n=93), GO (n=70), NEU (n=40), Gastroenterology (n=21), Infectious diseases (n=21), Algology (n=17), Internal medicine (n=10), Family medicine (n=2), Surgical oncology (n=1), and Urology (n=1).
The statistical comparisons demonstrated that the PMR group was similar to OT group (p=0.820), but had higher score than END (p=0.007), GO (p<0.001), and NEU (p<0.001) groups in terms of age (Table 1).
Considering gender differences, the Fisher’s exact test showed that the PMR group was similar to OT (p=0.180) and END (p=0.160) groups, but was different than GO (p<0.001), and NEU (p<0.001) groups (Table 1).
The Mann-Whitney U test showed that the PMR group was similar to GO group (p=0.257), but was different than OT (p<0.001), END (p=0.011), and NEU (p<0.001) groups in terms of BMI (Table 1).
Considering the osteoporosis frequency at lumbar spine, the Fisher’s exact test showed that the PMR group was similar to END (p=0.647) group, but was different than OT (p=0.001), GO (p=0.001), and NEU (p=0.041 groups (Table 2).
In terms of osteoporosis frequency at femur neck, PMR group was similar to OT (p=0.076), END (p=0.075) and GO (p=0.259) groups, but was different than NEU group (p=0.015) (Table 2).
Discussion
The current study aimed to provide a comparative view on the differences between PMR and other clinical branches considering DEXA-related data. The statistical comparisons demonstrated that PMR may be different from other clinical branches in terms of DEXA-related data. As expected, PMR, the clinical branch most related to the musculoskeletal system, was the clinic where DEXA was most frequently requested. In fact, it is likely that DEXA examinations requested by other branches were actually requested by PMR through consultation.
It is known that osteoporosis has extensive etiopathogenesis [8] and is associated with various health problems and diseases such as sarcopenia [9], diabetes mellitus [10], asthma [11], depression [12], rheumatoid arthritis [13], Sjögren’s syndrome [14], and breast cancer [15]. Therefore, besides PMR, many clinical branches may request DEXA for diagnosis of osteoporosis. However, it is not clear that the differences between PMR and other clinical branches in terms of DEXA-related data. In the present study, the PMR branch was compared to other clinical branches in terms of DEXA-related data including age, gender, and BMI of the patient for whom DEXA is requested, the osteoporosis frequency at lumbar spine, and the osteoporosis frequency at femur neck. To our knowledge, this study is the first to address DEXA-related data on a branch-based basis. In this respect, it could be an important contribution to the literature.
According to the results of the present study, the status of other clinical branches compared to the PMR in terms of DEXA-related data was as follows (Table 3): Considering age, OT was similar to PMR, while END, GO, and NEU were lower than PMR. Considering gender (F/M), OT and END were similar to PMR, while GO was higher, and NEU was lower than PMR. Considering BMD, while OT was higher, END and NEU were lower than PMR, GO was similar to PMR. Considering osteoporosis frequency at lumbar spine, while OT and GO were lower than PMR, END and NEU were similar to PMR. Considering osteoporosis frequency at femur neck, OT, END, and GO were similar to PMR, while NEU was lower than PMR. The differences in DEXA-related data seen between PMR and other clinical branches may be due to differences in patient profiles.
Limitation
On the other hand, possible limitations of this study should also be taken into consideration. For example, the retrospective design may result in missing data and the current study may be within this scope. In addition, it was a single-center trial and some groups had relatively small sample sizes. It was the first study on the research topic and due to no directly related literature, an in-depth comparative discussion including different results could not be performed.
Conclusion
In conclusion, osteoporosis has multifactorial nature and many clinical branches may be requested DEXA to diagnose this disease. The PMR is the most frequently clinic requesting DEXA than other clinical branches. Due to differences in patient profiles, some differences in DEXA-related data may be seen between PMR and other clinical branches.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and Human Rights Statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Funding: None
Conflict of Interest
The authors declare that there is no conflict of interest.
References
1. Adejuyigbe B, Kallini J, Chiou D, Kallini JR. Osteoporosis: Molecular pathology, diagnostics, and therapeutics. Int J Mol Sci. 2023;24(19):14583.
2. Föger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P. Osteoporosis: Pathophysiology and therapeutic options. EXCLI J. 2020;19:1017-37.
3. Farr JN, Fraser DG, Wang H, Jaehn K, Ogrodnik MB, Weivoda MM, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31(11):1920-29.
4. Mäkitie RE, Costantini A, Kämpe A, Alm JJ, Mäkitie O. New ınsights ınto monogenic causes of osteoporosis. Front Endo (Lausanne). 2019;10:70.
5. Sangondimath G, Sen RK, T FR. DEXA and ımaging in osteoporosis. Indian J Orthop. 2023;57(Suppl 1):82-93.
6. Hsu CL, Wu PC, Yin CH, Chen CH, Lee KT, Lin CL, et al. Clinical outcomes and cost-effectiveness of osteoporosis screening with dual-energy x-ray absorptiometry. Korean J Radiol. 2023;24(12):1249-59.
7. Arceo-Mendoza RM, Camacho P. Prediction of fracture risk in patients with osteoporosis: a brief review. Womens Health (Lond). 2015;11(4):477-484.
8. Valenzuela-Martínez S, Ramírez-Expósito MJ, Carrera-González MP, Martínez-Martos JM. Physiopathology of osteoporosis: Nursing ınvolvement and management. Biomedicines. 2023;11(4):1220;1-20.
9. Chen S, Xu X, Gong H, Chen R, Guan L, Yan X, et al. Global epidemiological features and impact of osteosarcopenia: A comprehensive meta-analysis and systematic review. J Cachexia Sarcopenia Muscle. 2024;15(1):8-20.
10. Prasad TN, Arjunan D, Pal R, Bhadada SK. Diabetes and osteoporosis. Indian J Orthop. 2023;57(Suppl 1):209-17.
11. Jha SS, Kumar M, Agrawal PK, Thakur DK. Osteoporosis in asthma and COPD. Indian J Orthop. 2023;57(Suppl 1):200-8.
12. Guo X, She Y, Liu Q, Qin J, Wang L, Xu A, et al. Osteoporosis and depression in perimenopausal women: From clinical association to genetic causality. J Affect Disord. 2024;356:371-8.
13. Deng Y, Wong MCS. Association between rheumatoid arthritis and osteoporosis in Japanese populations: A mendelian randomization study. Arthritis Rheumatol. 2023;75(8):1334-43.
14. Huang W, Tian J, He J. Risk factors of primary Sjögren’s syndrome combined with osteoporosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49(2):312-8.
15. Zhao F, Li C, Wang W, Zhang Y, Yao P, Wei X, et al. Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women. J Cancer Res Clin Oncol. 2024;150(2):102;1-14.
Download attachments: 10.4328.ACAM.22362
Veysel Delen, Ferit Dogan. Differences between physical medicine and rehabilitation and other clinical branches in terms of dual-energy x-ray absorbsiyometri (dexa)-related data. Ann Clin Anal Med 2025;16(Suppl 2):S91-94
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
The effect of asthma medications on ion concentration in carious and non-carious primary molar teeth
Yakup Dogru 1, Tamer Tuzuner 1, Nagehan Yilmaz 1, Yasin Alemdag 2, İbrahim Alp 3
1 Department of Pediatric Dentistry, Faculty of Dentistry, 2 Department of Mechanical Engineering, Faculty of Engineering, 3 Department of Mining Engineering, Faculty of Engineering, Karadeniz Technical University, Trabzon, Turkiye
DOI: 10.4328/ACAM.22407 Received: 2024-09-18 Accepted: 2024-12-09 Published Online: 2024-12-30 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S95-100
Corresponding Author: Yakup Dogru, Department of Pediatric Dentistry, Faculty of Dentistry, Karadeniz Technical University, Trabzon, Turkiye. E-mail: dtydogru@gmail.com P: +90 539 228 42 63 Corresponding Author ORCID ID: https://orcid.org/0000-0003-0587-5618
Other Authors ORCID ID: Tamer Tuzuner, https://orcid.org/0000-0001-5817-5928 . Nagehan Yilmaz, https://orcid.org/0000-0001-9523-2899
Yasin Alemdag, https://orcid.org/0000-0002-7470-4110 . İbrahim Alp, https://orcid.org/0000-0002-6032-3528
This study was approved by the Ethics Committee of the Medical Faculty of Karadeniz Technical University (Date: 2021-11-15, No: 2021/289)
Aim: Asthma is one of the most common childhood diseases. Evidence shows a positive correlation between the use of asthma medications and dental caries.
Material and Methods: The participants included in the study were categorized into four groups: healthy children with carious teeth (CH), children on asthma medication with carious teeth (CAM), healthy children with non-carious teeth (NCH), and children on asthma medication with non-carious teeth (NCAM). The element analysis of the extracted teeth was performed using inductively coupled plasma mass spectrometry (ICP-MS).
Results: The Mn levels of the CAM group were found to be statistically significantly higher than that of the NCAM group (p < 0.001). The CAM was found to have significantly higher levels of Cu than CH (p = 0.002). It was determined that the S levels of CH and CAM groups were statistically significantly higher than the NCH and NCAM groups, respectively. (p = 0.003, p < 0.01, p = 0.004, and p < 0.01, respectively ). The levels of Sr, Al, and Zr were also detected to be statistically significantly higher in the NCAM than in NCH (p = 0.002, p = 0.007, and p = 0.009, respectively).
Discussion: Regardless of whether there is tooth decay or not, higher levels of Sr, Zr, Cu, and Al elements were found in the teeth of children using asthma medications compared to the teeth of healthy children. The results obtained regarding the relationship between dental caries and Pb, Mn, Cu, Sr, Li, and S levels were similar to those reported by other studies in the literature. The results of our study regarding the correlation of Mo and Al with dental caries are different from those reported in some previous studies.
Keywords: Asthma, Dental Caries, Trace Element, Inductively Coupled Plasma Mass Spectrometry
Introduction
Asthma is a heterogeneous respiratory disease. It has symptoms such as wheezing, shortness of breath, chest tightness, and cough and is characterized by chronic airway inflammation. Furthermore, asthma can be accompanied by variable expiratory airflow limitation, which might become permanent [1]. The World Health Organization (WHO) has reported that asthma is one of the most common chronic childhood diseases [2]. Long-term controller medications and quick-relief medications are often used to manage asthma symptoms [3].
Dental caries is a biofilm disease that develops over time through complex interactions among various factors, including acidogenic bacteria, sugar-containing food, teeth, and saliva, thereby causing mineral loss in the teeth [4]. For decades, asthma has been referred to as a significant risk factor for caries formation, with recent studies corroborating this relationship [2]. This positive correlation between asthma and dental caries may be explained by the fact that asthma medications reduce salivary flow and reduce the oral pH below 7 [5]. In addition to the physiological effects of the medications, the method of their administration can also increase caries risk. For example, the prolonged oral stay of the drugs in case of improper inhaler use increases the risk of caries formation [6].
Previous studies have reported some trace elements to be closely associated with dental caries [7-14 ]. In some studies, molybdenum (Mo) [7], vanadium (V) [7], fluorine (F) [7, 8], strontium (Sr) [8-11], and lithium (Li) [7, 9] were reported to have a cariostatic effect, whereas selenium (Se) [7], lead (Pb) [7, 12, 13], manganese (Mn) [9, 14], copper (Cu) [7, 12] and zinc (Zn) [7] were reported to have a cariogenic effect.
Accordingly, the current study examines extracted carious and non-carious primary molars of healthy children and children on asthma medication to analyze changes in their ion concentrations and elaborate on how asthma medication affects the predisposition of children with asthma toward dental caries.
The null hypotheses of the current study are (a) there is no difference between the element levels in the carious teeth of healthy children and children on asthma medication, (b) there is no difference between the element levels in the non-carious teeth of healthy children and children on asthma medication.
Material and Methods
Patient Selection and Sample Collection
Pediatric patients who applied to our institution met the inclusion criteria and wanted to participate in the study were included in the study. For all the pediatric patients included in the study, their parents or legal guardians provided consent via written informed consent forms.
The sample size was determined based on the study of Tvinnereim et al. [15] and the calculations were made with alpha error = 0.05, beta error = 0.20, and an effect size of 1.3. According to these calculations, nine teeth for each group and a total of 36 teeth would be adequate for the sample size. However, considering the possible data losses, a total of 40 primary molars were included in the study.
In this study, primary molars extracted from different patients were evaluated. Carious teeth were extracted due to the presence of extreme caries, while non-carious teeth were extracted due to delayed physiological root resorption. The teeth included in the study were not restored. Dental pulp was not removed before the tooth extracts were prepared. The included patients were divided into four groups (n = 10 teeth for each group) of carious and non-carious teeth of healthy children and children on asthma medications. Group 1 included the carious teeth of healthy children (CH), group 2 included the carious teeth of children on asthma medication (CAM), group 3 included the non-carious teeth of healthy children (NCH), and group 4 included the non-carious teeth of children on asthma medication (NCAM).
Preparation And Analysis Of Samples
The teeth were extracted using suitable extraction techniques for primary molars without damaging the teeth. The extracted teeth were then rinsed with physiological saline and stored in formaldehyde fluid in a glass container until the completion of sample collection. The carious teeth had crowns and roots; however, some of the non-carious teeth that were extracted due to physiological resorption did not have roots. After the completion of sample collection, the teeth were ground along with the crown and roots using a ring grinder they were formed a powder, with the particles being less than 100 microns in size.
Following the grinding procedure, the powdered tooth samples were dissolved with aqua regia, after which the element levels in the samples were analyzed with ICP-MS (Perkin Elmer Nexion 2000).
Statistical Methods
Subsequently, the SPSS (Statistical Package for the Social Sciences, SPSS Inc. Chicago, IL, USA) 17.0 statistical package program was used to analyze the data obtained in the study. Descriptive statistics were given as mean ± standard deviation or median and min–max values. Kruskal–Wallis and Mann–Whitney U tests, as well as Bonferroni correction, were utilized for multiple intergroup comparisons, with Mann–Whitney U test being used for paired comparisons. Spearman’s correlation test was performed to assess the element levels in the carious and non-carious teeth of children who were on asthma medication. Since the values obtained in the analyses of some element levels were under the threshold value, the number of samples was inadequate for some groups for the analysis of these elements. Therefore, the groups where the number of samples collected was insufficient for the statistical analysis of these elements were excluded from the comparison, and their critical p values were calculated again by the Bonferroni correction. p < 0.05 was considered statistically significant.
Ethical Approval
This study was approved by the Ethics Committee of the Medical Faculty of Karadeniz Technical University (2021-11-15, No:2021/289).
Results
There was no statistically significant difference among the groups for Pb levels (p > 0.05). The Mn levels of the CAM group were found to be statistically significantly higher than those of the NCAM group (p < 0.001). The Cu levels of the CH group were statistically significantly lower than that of the CAM group, and the CH group was statistically significantly higher than that of the NCH group (p = 0.002, p < 0.01, and p < 0.001, respectively). The Cu levels of the CAM group were found to be statistically significantly higher than those of the NCAM group (p < 0.001). It was determined that the S level of CH was statistically significantly higher than the S level of NCH, and the S level of CAM was statistically significantly higher than the S level of NCAM. (p = 0.003, p < 0.01, p = 0.004, and p < 0.01, respectively ). Sr levels in the NCAM group were found to be statistically significantly higher than those in the NCH group (p = 0.002; p<0.01, respectively). The Al levels of the NCH group were found to be statistically significantly lower than that of the NCAM group (p = 0.007;p < 0.01, respectively). The Zr levels of the NCH group were found to be statistically significantly lower than that of the NCAM group (p = 0.009;p < 0.01, respectively). There was no statistically significant difference among the groups in terms of Mo and Li levels (p > 0.05) (Table 1).
According to the correlation coefficients of the element levels detected in the carious teeth of children using asthma medication, the element pairs Cu–Mo and Mn–Li was in the moderate positive correlation of statistical significance (r = 0.689, p = 0.028; p < 0.05, r = 0.654, p = 0.04; p < 0.05, respectively), Al–Sr, S–Mo, and Mn–Mo were in the strong positive correlation of statistical significance (r = 0.778, p = 0.008; p < 0.01, r = 0.758, p = 0.011; p < 0.05, r = 0.738, p =0.015; p < 0.05, respectively ), Pb–Li were in the moderate negative correlation of statistical significance (r = −0.654, p = 0.04; p < 0.05) (Table 2).
According to the correlation coefficients of the element levels detected in the non-carious teeth of children on asthma medications, the element pairs of Al–Sr, Cu–Li, and Mn–Mo were in strong positive correlation of statistical significance (r = 0.849, p = 0.002; p < 0.01, r = 0.834, p = 0.01; p < 0.05, r = 0.726, p = 0.027; p < 0.05, respectively), the Sr–Pb pair was in strong negative correlation of statistical significance (r = −0.802, p = 0.017; p < 0.05, respectively), and the Mn–Zr pair was in moderate negative correlation of statistical significance (r = −0.661, p = 0.038; p < 0.05, respectively) (Table 3).
Discussion
The results of our study showed that there were significant differences in the levels of elements evaluated in carious and non-carious teeth between children using asthma medication and healthy children, and therefore, the null hypotheses were rejected.
Compared with other analysis techniques, ICP-MS and Inductively Coupled Plasma – Optical Emission Spectroscopy (ICP-OES) is more advantageous since they have appropriate limits of detection, allows simplicity in preparing samples for analysis, provides ease of injection, requires only small quantities of samples for analysis, allows the simultaneous analysis of multiple elements, achieve high accuracy and sensitivity in analysis results, and facilitate easy data processing [16]. In this study, ICP-MS was preferred because it has a wider detection limit range.
As a result of the data we obtained, it was found that the Pb level of NCAM was higher than NCH, and the Pb level of CAM was higher than CH, which was not statistically significant. Yalçın et al., [17] on the other hand, studied the dental and blood samples collected from healthy children and children with asthma. They reported that blood and tooth Pb levels were similar in the asthma group and the control group, and no significant difference was reported between the two groups.Increased Pb levels in tissues and body fluids affect IL-4 synthesis and result in increased IgE synthesis by B lymphocyte cells, thereby indirectly affecting the mechanism of asthma [18]. This further explains the relationship between asthma and high Pb levels in tissues and body fluids. In the present study, on evaluating Pb levels in carious and non-carious teeth, they were found to be higher in the carious teeth of both the healthy children and children of asthma medication, with no statistically significant difference among the groups (p > 0.05). Overall, above mentioned possible positive correlations between Pb and dental caries can be explained by Pb being a divalent cation (Pb+2) and the fact that it replaces the isovalent fields of Ca in hydroxyapatite crystals, which are among the basic structures of dentine tissue [19].
In a study where Yalçın et al. [17] analyzed the levels of elements in the blood and teeth samples collected from healthy children and children with asthma. The Mn levels in the samples were only slightly higher in healthy children than in those with asthma, and no statistically significant differences were found among the groups (p>0.05). In a study where Soutar et al. [20] focused on the role of Mn in asthma, it was suggested that Mn intake was inversely proportional to bronchial reactivity.However, as per the results of the current study, the Mn levels were found to be slightly higher in the NCAM group than in the NCH group, with no significant difference between them (p>0.05). Considering the involvement of Mn in dental caries, it has been suggested that Mn stimulates the metabolism of dental caries-causing bacteria, such as Streptococcus mutans, facilitates sucrose-associated biofilm development, and protects against the oxidative stresses that occur during dental plaque formation [21]. According to the results of this study, the Mn level of CAM was found to be statistically significantly higher than the Mn level of NCAM (p<0.001), in the presence of caries, Riyat et al. [9] and Poletto et al. [14] also detected statistically significantly higher levels of Mn in the teeth and saliva, respectively. These findings are consistent and may also indicate the medication-based increase for the present study. Possibly, caries existence could elevate the absorbed amount of Mn in primary teeth tissue.
Considering that increased Cu levels can incapacitate the antioxidant system and indirectly cause inflammation, which is a primary symptom of asthma [22], a positive correlation between asthma and Cu can be suggested. In the present study, the Cu levels were statistically significantly higher in the CAM group than in the CH group (p = 0.002), while the Cu levels were only slightly higher in the NCAM group than in the NCH group, with no statistical difference between the groups (p>0.05). These findings are consistent with another study [23], in which asthmatic patients were found to have higher serum Cu levels. Furthermore, in the present study, Cu levels were found to be increased in the presence of dental caries in both healthy children and children on asthma medication. The literature presents different findings regarding Cu’s involvement in dental caries. Additionally, there is one study that found higher levels of Cu in carious teeth [12] and another study that reported lower levels of Cu in carious teeth [13].
In the present study, the Sr levels were also found to be statistically significantly higher in the NCAM group than in the NCH group (p=0.002). Regarding the association between Sr and dental caries, when used in specific concentrations, it is known that the combination of Sr and fluoride enhances enamel remineralization in vitro experiments [8]. In the current study, The Sr level of NCH was higher than CH, and the Sr level of NCAM was higher than CAM. Based on the correlation coefficients of the non-carious teeth of children using asthma medication, a statistically strong negative correlation was found between Sr and Pb, which, to the best of our knowledge, are considered to be cariostatic and cariogenic, respectively, according to the literature. (r=-0.802,p=0.017;p<0.05, respectively). Both Li et al. [10] and Riyat et al. [9] has reported higher Sr levels in non-carious teeth than in carious teeth. This negative correlation between Sr and the presence of dental caries can be explained by the fact that Sr shrinks the hydroxyapatite crystal surface, making it harder to dissolve, thereby reducing its solubility as Sr covers the crystal surfaces and inhibits bacterial growth that could be considered as consistent to our findings including non-carious teeth samples [10].
The present study reported slightly higher levels of Mo in the CAM group than in the CH group; however, no statistical difference was observed between the two groups (p>0.05). A study in Hungary that investigated the relationship between dental caries and Mo found that children living in an area where the drinking water contained Mo had lower rates of dental caries than those living in an area with no Mo content in the drinking water [7]. In the present study, Mo levels were higher in the CAM. However, no significant difference was found between the CAM and NCAM groups in terms of Mo levels (p>0.05). Since the amount of previously published articles is very limited, this finding may also require further investigation.
Tanaka et al. also found that Al levels in the enamel of non-carious teeth were significantly higher than that in the enamel of carious teeth and that the Al levels were significantly higher in the dentin of non-carious teeth than in that of carious teeth. It has been said to inhibit bacterial growth and reduce bacterial growth and reduce bacterial colonization on enamel surfaces [24]. In the present study, Despite Al levels being significantly lower in the NCH group than in the NCAM group (p=0.007), no significant differences were found between CH-NCH and CAM-NCAM. These contradictory findings may be related to the sample size inadequacy that should be further investigated. However, a statistically significant positive correlation was observed between the Al–Sr levels in the carious and non-carious teeth of children on asthma medication (r = 0.778, p = 0.008; p < 0.01, r = 0.849, p = 0.002; p < 0.01, respectively) which may indicate the possible cariostatic effect of Al and Sr irrespective of the asthma medication usage.
Lithium has been reported to reduce the incidence of dental caries [7]; Riyat et al. [9] found higher levels of Li in non-carious teeth. In the current study as well, the NCAM group showed higher levels of Li than the CAM group, but there was no statistically significant difference between the groups (p>0.05). The results of the current study may also support the cariostatic effect of Li.
In the current study, Zr levels were found to be statistically significantly higher in the NCAM group than in the NCH group (p=0.009). To the best of our knowledge, there is only one study that has investigated the relationship of Zr with dental caries and asthma, and these studies have been unable to detect this element in teeth and blood [11].
To the best of our knowledge, the effect of S on cariogenicity has not been investigated adequately. According to the results of the current study, the S level of CAM was statistically significantly higher than NCAM, and the S level of CH was found to be statistically significantly higher than NCH (p=0.004, p=0.003, respectively). In their study, Yamaguchi et al. found that hydroxyapatite in the enamel structure had a smaller and more ambiguous crystal configuration in teeth exposed to hydrogen sulfide [25]. These changes generated by an S-containing compound in the enamel may be closely associated with the increase in its level in the presence of dental caries, as consistent with our findings.
For the other paired correlation coefficients obtained in this study, to the best of our knowledge, no relationship was found to form a basis in the literature. This issue should also be investigated in future studies.
There are some limitations of this study. Increasing the total number of teeth can help attain higher clarity and precision in the results. Furthermore, there is no complete standardization on the duration of the medications used by the children with asthma and possible rehabilitation conditions. Recall collected from the patients with asthma and their parents were obtained verbally and then confirmed with the information available from the electronic database in our clinic. Despite detailed recall, there may still be errors because of potentially incorrect information reported by the parents. The depth and extent of the carious lesions on the collected carious teeth from both healthy children and children on asthma medication have not been standardized. The above issues may affect the results of the analyses.
In conclusion, regardless of the presence of dental caries, the teeth of children who were on asthma medication had higher Sr, Zr, Cu, and Al elements compared to healthy children’s teeth. This finding is one of the most noteworthy results of this study. The current study reported higher levels of Cu and S in the carious teeth of healthy children and children on asthma medications compared with non-carious teeth. In addition, children on asthma medications were found to have higher levels of Mn in their carious teeth than in their non-carious teeth. These results also provide important data regarding the relationship between caries, elemental composition, and the use of asthma medication.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article. This study was produced from the thesis number YOKTEZ-725654 prepared by Yakup Dogru, under the supervision of Tamer Tüzüner.
Animal and Human Rights Statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Funding: This study was supported by Karadeniz Technical University Scientific Research Projects Unit-THD-2022-10058.
Conflict of Interest
The authors declare that there is no conflict of interest.
References
1. Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17-35.
2. Hassanpour K, Tehrani H, Goudarzian M, Beihaghi S, Ebrahimi M, Amiri P. Comparison of the frequency of dental caries in asthmatic children under treatment with inhaled corticosteroids and healthy children in Sabzevar in 2017-2018. Electron J Gen Med. 2019;16(2):6.
3. Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403-407.
4. Dayo AF, Wolff MS, Syed AZ, Mupparapu M. Radiology of Dental Caries. Dent Clin North Am. 2021;65(3):427-445.
5. Paganini M, Dezan CC, Bichaco TR, de Andrade FB, Neto AC, Fernandes KBP. Dental caries status and salivary properties of asthmatic children and adolescents. Int J Paediatr Dent. 2011;21(3):185-191.
6. Stensson M, Wendt LK, Koch G, Oldaeus G, Birkhed D. Oral health in preschool children with asthma. Int J Paediatr Dent. 2008;18(4):243-250.
7. Pathak MU, Shetty V, Kalra D. Trace elements and oral health: A systematic review. J Adv Oral Res. 2016;7(2):12-20.
8. Thuy TT, Nakagaki H, Kato K, Hung PA, Inukai J, Tsuboi S, et al. Effect of strontium in combination with fluoride on enamel remineralisation in vitro. Arch Oral Biol. 2008;53(11):1017-1022.
9. Riyat M, Sharma DC. Analysis of 35 inorganic elements in teeth in relation to caries formation. Biol Trace Elem Res. 2009;129(1):126-129.
10. Li Z, He M, Peng B, Jin Z. Strontium concentrations and isotope rations in enamel of healthy and carious teeth in southern Shaanxi, China. Rapid Commun Mass Spectrom. 2013;27(17):1919-1924.
11. Riyat M, Sharma DC. Significance of trace element profile of blood of persons with multiple caries versus sound teeth. Biol Trace Elem Res. 2010;134(2):174-179.
12. Alomary A, Momani IA, Obeidat S, Massadeh A. Levels of lead, cadmium, copper, iron, and zinc in deciduous teeth of children living in Irbid, Jordan by ICP-OES: some factors affecting their concentrations. Environ Monit Assess. 2013;185(4):3283-3295.
13. Amr MA, Helal AFI. Analysis of trace elements in teeth by ICP-MS: Implications for caries. J Phys Sci. 2010;21(2):1-12.
14. Poletto AC, Singi P, Barri RM, Casanova AA, Garbelini CCD, da Silva CC, et al. Relationship of levels of trace elements in saliva and dental caries in preschool children using total reflection X-ray fluorescence technique (TXRF). J Trace Elem Med Biol. 2021;63:126663.
15. Tvinnereim HM, Eide R, Riise T. Heavy metals in human primary teeth: Some factors influencing the metal concentrations. Sci Total Environ. 2000;255(1-3):21-27.
16. Hill SJ, Fisher A, Faulkes M. Hill SJ editor. Basic Concepts and Instrumentation for Plasma Spectromety. Inductively Coupled Plasma Spectrometry and its Applications. Oxford: Blackwell Publishing; 2007.p.61-97.
17. Yalcin SS, Emiralioğlu N, Yalcin S. Evaluation of blood and tooth element status in asthma cases: A preliminary case-control study. BMC Pulm Med. 2021;21(1):1-8.
18. Sun L, Hu J, Zhao Z, Li L, Cheng H. Influence of exposure to environmental lead on serum immunoglobulin in preschool children. Environ Res. 2003;92(2):124-128.
19. Haller LA, Olmez I, Baratz R, Rabinowitz M, Douglass CW. Dentin as a possible bio-epidemiological measure of exposure to mercury. Arch Environ Contam Toxicol.1993;25(1):124-128.
20. Soutar A, Seaton A, Brown K. Bronchial reactivity and dietary antioxidants. Thorax. 1997;52(2):166-170.
21. Kajfasz JK, Katrak C, Ganguly T, et al. Manganese uptake, mediated by SloABC and MntH, is essential for the fitness of Streptococcus mutans. Msphere. 2020;5(1):e00764-19.
22. Vural H, Uzun K, Uz E, Koçyigit A, Cigli A, Akyol Ö. Concentrations of copper, zinc and various elements in serum of patients with bronchial asthma. J Trace Elem Med Biol. 2000;14(2):88-91.
23. Kocyigit A, Armutcu F, Gurel A, Ermis B. Alterations in plasma essential trace elements selenium, manganese, zinc, copper, and iron concentrations and the possible role of these elements on oxidative status in patients with childhood asthma. Biol Trace Elem Res. 2004;97(1):31-41.
24. Tanaka T, Maki K, Hayashida Y, Kimura M. Aluminum concentrations in human deciduous enamel and dentin related to dental caries. J Trace Elem Med Biol. 2004;18(2):149-154.
25. Yamaguchi T, Hanabusa M, Hosoya N, Chiba T, Yoshida T, Morito A. Enamel surface changes caused by hydrogen sulfide. J Conserv Dent. 2015;18(6):427.
Download attachments: 10.4328.ACAM.22407
Yakup Dogru, Tamer Tuzuner, Nagehan Yilmaz, Yasin Alemdag, İbrahim Alp. The effect of asthma medications on ion concentration in carious and non-carious primary molar teeth. Ann Clin Anal Med 2025;16(Suppl 2):S95-100
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Programmed cell death 1 polymorphism in patients with rheumatoid arthritis and its impact on disease activity
Abdelnaser Badawy 1, 2, Ashraf Mohamed 3, Mohamed M Abd El Mawgod 4, 5, Ghada Awadalla 6, Ehsan Rizk 7, Emad Elmasry 7
1 Department of Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia, 2 Department of Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt, 3 Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt, 4 Department of Family and Community Medicine, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia, 5 Department of Public Health and Community Medicine, Faculty of Medicine, Al Azhar University. Assiut Egypt, 6 Department of Biochemistry, Animal Health Research Institute, Mansoura Branch, Giza, Egypt, 7 Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
DOI: 10.4328/ACAM.22453 Received: 2024-10-15 Accepted: 2024-11-18 Published Online: 2024-12-29 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S101-104
Corresponding Author: Mohamed M. Abd El-Mawgod, Department of Family and Community Medicine, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia. E-mail: mossa20072006@yahoo.com P: +966 501 171 525 Corresponding Author ORCID ID: https://orcid.org/0000-0002-6351-2359
Other Authors ORCID ID: Abdelnaser Badawy, https://orcid.org/0000-0002-4966-3839 . Ashraf Mohamed, https://orcid.org/0000-0003-33.2-1177 . Ghada Awadalla, https://orcid.org/0009-0006-9812-7676 . Ehsan Rizk, https://orcid.org/0000-0003-3725-6571 . Emad Elmasry, https://orcid.org/0009-0006-1792-7592
This study was approved by the Ethics Committee of Mansoura University, Faculty of Medicine (Date: 2018-05-18, No: 188)
Aim: This study aimed to assess the role of the single nucleotide polymorphism PD-1.5 C/T (7209C/T) in rheumatoid arthritis (RA) development and its effect on disease activity in the Egyptian population.
Material and Methods: A case-control study was done on 240 patients diagnosed with RA and 200 age-matched healthy individuals, which considered the control group. The PD-1.5 (7209 C/T) polymorphism was analyzed by RFLP-PCR.
Results: When comparing RA patients to controls, there was a higher incidence of 7209 TT genotype. (P =0.000, OR (95% CI) =14(4-50). The 7209 T allele was highly represented in the RA group as compared to the healthy control group (P =0.0001, OR (95% CI) =2.1(1.5-3.2). We found that the 7209 TT genotype was linked to more remission and mild state disease activity (P=0.004).
Discussion: PD-1.5 TT genotype and T allele were associated with RA in Egyptians.
Keywords: Gene Polymorphism, Pd-1.5, Rheumatoid Arthritis, Autoimmune Diseases, Disease Activity.
Introduction
Autoimmune diseases are caused by the interaction between genetic susceptibility and environmental factors. Genetic liability to autoimmune diseases is complex and includes multiple genes that organize the functions of different immune cells [1]. Human genome polymorphisms have been analyzed, and new evidence of genetic susceptibility to autoimmune diseases has been discovered. [2] RA is a chronic autoimmune disorder manifested by elongated T-cell response, which evaded the normal regulatory immune mechanisms. CD4+ T cells have been suggested as the most disease-relevant cell type in rheumatoid arthritis, and multiple genes inside RA susceptibility loci are involved in the regulation and differentiation pathways of CD4+ T cells [3].
The pathophysiology of RA is complicated and mainly results in chronic arthritis and may cause systemic affections in many individuals [4]. As the actual cause of RA is still unclear, it is hypothesized that the dysregulation in the activation of T lymphocytes has a remarkable role in auto-reactivity by destroying immune tolerance [5].
The programmed cell death 1 (PDCD1) gene, also named PD-1, is situated on the chromosomal region 2q37 and expresses PD-1 protein, a 55-kDa, is a transmembrane protein and has one extra-cellular domain Ig V-like and other cytoplasmic domain of a 97-amino acid which contains two immunotyrosine motifs, one switch and another inhibitory [6].
It also has a role in the induction and persistence of T cell tolerance, which prevents tissue damage caused by effector T cell responses [7]. The pivotal role of PD-1 in regulating immune response is discovered by studies on gene disturbance that explain the specific genotype-phenotype for autoimmune disorders [8].
The PD-1.5 gene C/T polymorphism gene at 7209 is a functional one and can affect the transcription and expression of the PD-1 protein. Genetic studies suggested that there was a link between PD-1 variants and predisposition to autoimmune disorders such as RA [9]. Although the susceptibility to autoimmune disorders has been debatable, the current study aims to assess what part PD-1.5 (7209C/T) variants play in the susceptibility to RA in the Egyptian population.
Material and Methods
240 RA patients, 196 (81.7%) females and 44 (18.3%) males, were selected for our case-control study from the rheumatology and immunology outpatient department of Mansoura University Hospital, Mansoura University, Egypt.
The diagnosis of RA was based on the ACR diagnostic criteria [10]. Two hundred healthy individuals, 172 (86%) females and 28(14%) males, who have no history of autoimmune disorders and are negative for the ANA test, were considered the control group.
We collected clinical, epidemiological, and familial RA data from all participants using medical records and questionnaires. All clinical and demographic information, the disease activity score in 28 joints (DAS28), and laboratory results for CBC, ESR, CRP, RF, and anti-citrullinated protein antibodies (ACPA) were also recorded.
Patients with organ failure, chronic infection, autoimmune diseases, and malignancy were not included in this study.
Blood Sample Collection
One ml peripheral blood sample was collected from each subject and withdrawn in an EDTA tube for fresh DNA isolation, and extracted DNA was stored at -80º C until the later use for detection of the PD-1.5 C/T polymorphism.
DNA Extraction and genotyping of PD-1.5 C/T (rs2227981) polymorphism
Genomic DNA was extracted from whole blood samples using a DNA purification kit (Qiagen GmbH, Cat. No. 51104, and Hiden, Germany) [11]. Two sets of primers were designed for each polymorphism: forward 5-ACGGCCTGCAGGACTCAC-3 and reverse 5-AGGCAGGCACATATGTG-3. PCR program was done as follows: DNA was initially denatured for 5 min at 96˚C and then 30 cycles of denaturation for 60 sec at 95˚C, primer annealing for 60 sec at 56˚C, and primer extension for 60 sec at 72˚C. Extension was finally done for 7 min at 72˚C. The PCR product was 225bp. Digestion was done with BstUI restriction enzyme. The C allele gave 172 and 53bp bands while the T allele remained 225bp, as in Figure 1.
Statistical analysis
The data was entered, cleaned, and analyzed using SPSS version 22 (IBM SPSS Statistics V22.0). Qualitative data were shown as numbers and percentages, whereas numerical data were shown as means and standard deviations. The Hardy-Weinberg Equilibrium was employed to examine the genotype and allele frequencies in the two groups. To compare numerical data, the t-test was used, while the Chi-square test was used for categorical data. P< 0.05 was considered significant at a 95% confidence interval.
Ethical Approval
This study was approved by the Ethics Committee of Mansoura University, Faculty of Medicine (Date: 2018-05-18, No: R.18.05.188).
Results
Table 1 displays clinical and biochemical information for both RA patients and the control group. The DAS28 score, ESR, CRP, RF, and ACPA values of RA patients were highly significant, but the control group’s mean hemoglobin level was significantly higher. Regarding age, gender, and the distribution of body mass index (BMI), there was little variation between the control and patient groups.
PCR determination of PD-1.5(7209C/T) polymorphism in RA patients showed that there was a higher frequency of 7209 TT genotype in the patient’s group when compared with the controls (P =0.000, OR (95% CI) =14(4-50). In the recessive model, the risk for the development of RA was increased in individuals with TT genotype (P =0.000, OR (95% CI) =21 (6.5-71). The 7209 T allele was highly frequent in the RA group as compared to the healthy group (P=0.0001, OR (95% CI) =2.1(1.5-3.2) as illustrated in Table 2.
Various genotypes and alleles of PD-1.5 polymorphism are displayed in Table 3. There was no correlation between PD-1.5 genotypes and/or alleles and all clinical and laboratory markers in RA patients.
Discussion
The average life expectancy is reduced by three to ten years due to RA, a chronic systemic inflammatory disease that mostly affects the small joints of the hands and feet. With a 60% estimated heritability, RA is a multigene illness with a significant genetic component [3]. Genes involved in T-cell responses might be involved in the development of RA [12]. An inhibitory receptor called PD-1 controls the immune system and inhibits the onset of autoimmune diseases [13]. An increased incidence of autoimmune illnesses, including rheumatoid arthritis (RA), is strongly linked to polymorphism of the PDCD1 gene for the PD-1 protein. This finding raises the possibility that PD-1 plays a role in the pathophysiology of these diseases [8]. Many researchers looked at how PD-1 gene polymorphisms affect RA vulnerability however, the results are still unclear.
When comparing the patients’ group to the controls, our research revealed a higher occurrence of the T allele and the TT genotype (P =0.000 & P =0.0001, respectively). Our results matched Susanne S et al. [14] found that the occurrence of RA in the T allele was linked to an increased vulnerability to RA, and the T allele was proven to be a significant marker of RA. Conversely, Zou et al. [9] in China did not discover any link between PD-1.5 C/T polymorphism and RA among the Chinese population.
In another research, Yuming Z et al. [9] reported that there is no significant association between PD-1.5 C/T polymorphism and the risk of RA. Moreover, the T allele of the PD1.5 (rs2227981) C/T polymorphism was related to the RA risk among Chinese RA patients from Taiwan but not from Hong Kong. [15] An Iranian study examined the role of PD1.1 at position -538 in the promoter region of the PD-1 gene and found that this polymorphism is linked to a higher incidence of RA when compared to controls (2.9% vs. 0.7%, OR= 3.735, p=0.046) [16].
The PD-1.5 gene is situated at exon five and is considered an equivalent variation that fails to change the amino acid sequence of the PD-1 protein. This important relationship may be attributed to this variant with other PD-1 gene polymorphisms through linkage disequilibrium; this link may affect PD-1 expression at mRNA and protein levels [17]. Previous research found increased PD-1 expression in T lymphocytes [18] and increased PD-1 protein levels in RA [11]. This leads us to investigate whether PD-1 polymorphism may be responsible for altered PD-1 expression in RA. The blood levels of apoptotic markers were not investigated, which may have been considered a limitation of this study, as the serum levels of apoptotic markers may give a clearer idea about the role of PD-1 in the disease susceptibility and progression.
Belkhir et al. [19] reported that the PD1.3 (rs11568821) in Swedish patients polymorphism showed a tendency toward association with RA; however, it was not observed in a population from southeast China or populations from southern Brazil or Japan. PD 1.5 C/T polymorphism was examined in other diseases as a previous study found an association of PD 1.5 C/T polymorphism with gastric cancer in the Iranian population [20] and other autoimmune diseases like Systemic Lupus Erythematosus (SLE) in Malaysian and Indian populations [21].
The differences in the frequency of alleles and genotypes between our results and other research might be explained by the heterogeneity of RA disease, different races, different sample sizes, and the methodology by which this polymorphism was examined.
Regarding the association between PD1.5 polymorphisms and the clinical and laboratory data in the RA group, we demonstrated no correlation between PD-1 genotypes and/or alleles and all clinical and laboratory markers in RA patients. Also, we found that the TT genotype was linked to more remission and mild state disease activity (P=0.004). So, we can postulate the TT genotype is associated with a risk for RA but with milder disease.
Conclusion
We concluded that the TT genotype and T allele of PD-1.5 polymorphism may increase RA susceptibility among the Egyptian population. Other polymorphisms in the programmed cell death genes should be investigated on a large scale. Study the level of PD-1 altogether with its gene polymorphism may give better explanation of the effect of PD-1 in RA.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and Human Rights Statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Funding: None
Conflict of Interest
The authors declare that there is no conflict of interest.
References
1. Pisetsky DS, Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-24.
2. Kara S, Pirela-Morillo GA, Gilliam CT, Wilson GD. Identification of novel susceptibility genes associated with seven autoimmune disorders using whole genome molecular interaction networks. J Autoimmun. 2019;97:48-58.
3. Ha E, Bang SY, Lim J, Yun JH, Kim JM, Bae JB, et al. Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4+ T cells through differential DNA methylation, explaining a substantial proportion of heritability. Ann Rheum Dis. 2021;80(7):876-83.
4. Dedmon LE. The genetics of rheumatoid arthritis. Rheumatology. 2020;59(10):2661-70.
5. Pabon-Porras MA, Molina-Rios S, Florez-Suarez JB, Coral-Alvarado PX, Mendez-Patarroyo P, Quintana-Lopez G. Rheumatoid arthritis and systemic lupus erythematosus: Pathophysiological mechanisms related to the innate immune system. SAGE Open Med.2019;7:1-24.
6. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341-8.
7. Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and Role of Regulatory T Cells in Rheumatoid Arthritis. Front Immunol. 2021;12:1-12.
8. Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Frontiers in Immunology. 2023;14:1-13.
9. Zou Y, Zhang Z, Liu Y, Liu D, Xu W. Are programmed cell death one gene polymorphisms correlated with susceptibility to rheumatoid arthritis?: A meta-analysis. Medicine. 2017;96(35):e7805.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
11. Wang SC, Chen YJ, Ou TT, Wu CC, Tsai WC, Liu HW, et al. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J Clin Immunol. 2006;26(6):506-11.
12. Carle C, Degboe Y, Ruyssen-Witrand A, Arleevskaya MI, Clavel C, Renaudineau Y. Characteristics of the (Auto) Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database. Int J Mol Sci. 2023;24(5):1-20.
13. Fathi F, Sadeghi E, Lotfi N, Hafezi H, Ahmadi M, Mozafarpoor S, et al. Effects of the programmed cell death 1 (PDCD1) polymorphisms in susceptibility to systemic lupus erythematosus. Int J Immunogenet. 2020;47(1):57-64.
14. Schulz S, Zimmer P, Putz N, Jurianz E, Schaller HG, Reichert S. rs2476601 in PTPN22 gene in rheumatoid arthritis and periodontitis-a possible interface? J Transl Med. 2020;18(1):389.
15. Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, et al. Association of a programmed death one gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 2004;50(3):770-5.
16. Tahoori MT, Pourfathollah AA, Akhlaghi M, Daneshmandi S, Nicknam MH, Soleimanifar N. Association of programmed cell death-1 (PDCD-1) gene polymorphisms with rheumatoid arthritis in Iranian patients. Clin Exp Rheumatol. 2011;29(5):763-7.
17. Yang M, Liu Y, Zheng S, Geng P, He T, Lu L, et al. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: A meta-analysis based on 50 studies. Aging (Albany, NY). 2024;16(7):6068-6097.
18. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955-72.
19. Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A,Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatic occur after immune checkpoint inhibitor treatment.Ann Rheum Dis 2017;76:1747-1750.
20. Savabkar S, Azimzadeh P, Chaleshi V, Mojarad EN, Aghdaei HA. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. Gastroenterol Hepatol Bed Bench. 2013;6(4):178.
21. Chua KH, Lian LH, Sim XJ, Cheah TE, Lau TP. Association between PDCD1 gene polymorphisms and risk of systemic lupus erythematosus in three main ethnic groups of the Malaysian population. International Journal of Molecular Sciences. 2015;16(5):9794-803.
Download attachments: 10.4328.ACAM.22453
Abdelnaser Badawy, Ashraf Mohamed, Mohamed M Abd El Mawgod,Ghada Awadalla, Ehsan Rizk, Emad Elmasry. Programmed cell death 1 polymorphism in patients with rheumatoid arthritis and its impact on disease activity. Ann Clin Anal Med 2025;16(Suppl 2):S101-104
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Brucellosis case presenting with bicytopenia due to hemophagocytic syndrome
Filiz Kurklu Bozkır 1, Seval Sönmez Yildirim 1, Rafiye Ciftciler 2
1 Department of Infectious Diseases and Clinic Microbiology, 2 Department of Hematology, Aksaray University Training and Research Hospital, Aksaray, Turkey
DOI: 10.4328/ACAM.21710 Received: 2023-04-01 Accepted: 2023-08-14 Published Online: 2024-10-23 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S105-107
Corresponding Author: Filiz Kurklu Bozkir, Department of Infectious Diseases and Clinic Microbiology, Aksaray University Training and Research Hospital, Aksaray, Turkey. E-mail: dr.filizkurklu@hotmail.com P: +90 505 574 90 48 Corresponding Author ORCID ID: https://orcid.org/0000-0002-5114-8828
Hemophagocytic syndrome is a rare syndrome of excessive inflammation and tissue destruction due to abnormal immune activation and inflammation. Brucellosis is one of the rare causes of hemophagocytosis. Several reports revealed the relationship between hemophagocytosis and brucellosis. In this case, a case of brucellosis presenting with bicytopenia due to hemophagocytic syndrome is presented by blood and bone marrow culture analyses. The Rose Bengal test, Coombs’ test and the standard tube agglutination test were performed and were negative. Brucella melitensis was isolated in the blood and bone marrow cultures on the seventh day of incubation. After the diagnosis was confirmed by bone marrow biopsy and blood culture analyses, antibiotic treatment (oral doxycycline 200 mg/day and rifampicin 600 mg/day for 6 weeks) was immediately initiated. Bone marrow aspiration biopsy has shown platelets, neutrophils,
and lymphocytes phagocytosed by macrophages. Peripheral blood counts of the patient returned to normal levels after 2 weeks of antibiotic treatment of brucellosis. Antibiotic treatment was stopped after 6 weeks of therapy once patient’s complaints have resolved.
Keywords: Hemophagocytic Lymphohistiocytosis, Hepatosplenomegaly, Brucellosis
Introduction
Hemophagocytosis is a pathological and clinical case triggered by phagocytosis of erythrocytes, leukocytes, platelets and their precursor cells, which are the main components of bone marrow cells of macrophages activated for various reasons. Hemophagocytosis is also called hemophagocytic lymphohistiocytosis (HLH). Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by a hyperimmune response. HLH can be classified as primary and secondary. Primary HLH is associated with mutations of syntaxin 11, perforin 1, and hMunc13-4 genes and usually presents during infancy. Secondary HLH is mainly related to viral, bacterial, fungal or parasitic infections, malignancy, and autoimmune diseases [1]. Clinical diagnoses of HLH are high fever, hepatosplenomegaly (HSM), cytopenia (in 2 cell types), elevated ferritin (> 500 ng/dL), high triglyceride (> 265 mg/dL) or hypofibrinogenemia (< 150 mg/dL), deficiency or absence of NK cell activity, elevated CD25 levels, and hemophagocytosis in the bone marrow, spleen, lymph node, or liver. Five of these eight criteria must be fulfilled for successful diagnosis [2, 3]. Brucellosis is one of the most common zoonotic diseases in the world and Türkiye, and can progress with various complications [4]. The relationship between brucellosis and hemophagocytosis exists in the literature. In this case report, we present a secondary HLH case associated with Brucella, which is rarely reported in the literature.
Case Report
A 19-year-old male patient, who is a stock farmer, was admitted to the hospital with complaints of fever, diarrhea, decreased appetite and headache for 10 days. On the physical examination, right upper quadrant tenderness to palpation and hepatosplenomegaly were observed. The blood test results were as follows: hemoglobin: 15.3 g/dL, platelets: 60.103/μL, white blood cell: 3.000 /μL (neutrophil: 980), blood urea nitrogen
(BUN): 24 mg/dL, creatine: 0.7 mg/dL, AST: 131 U/L, ALT: 127 U/L, total bilirubin: 0.6 mg/dL, direct bilirubin: 0.1 mg/dL, LDH: 1125 U/L, triglyceride: 346 mg/dL, creatine kinase: 273 IU/L, CRP : 61 mg/dL, sedimentation: 3 mm/h and ferritin: 1486 ng/ mL (Table 1). Hepatitis viral markers and anti-HIV test results were found to be negative. No bacterial growth was detected in urine and stool cultures. Based on the past medical history and blood test results, the patient was diagnosed with Salmonellosis, and ciprofloxacin 2x 400 mg IV/day treatment was initiated. Echocardiography result of the patient revealed that no vegetation was established. Rose Bengal (RB), Brucella Coombs and standard tube agglutination (STA) tests were found to be negative. Since the fever of the patient was still high and
thrombocyte (PLT) and white blood cell (WC) results were respectively 35.103/μL and 1970/μL, bone marrow aspiration biopsy was performed to diagnose fever. In addition to the existence of high fever, HSM, bicytopenia, and high ferritin levels in the patient, observation of platelets, neutrophils and lymphocytes phagocyted by macrophages in the bone marrow peripheral smear test allowed us to consider secondary hemophagocytosis syndrome due to Brucella infection. On the seventh day, the growth of Brucella Melitensis was detected in the blood and bone marrow cultures. Ciprofloxacin treatment was stopped. Doxycycline 2×100 mg/day/po and rifampicin 600 mg/day/po treatment was initiated for the patient. On the tenth day of the therapy, the Rose Bengal test result was positive and the standard tube agglutination test (STA) was detected to be 1/640. The patient was discharged after improvement of laboratory and clinical symptoms. Doxycycline 2×100 mg/day/po and rifampicin 600 mg/day/ po treatment was continued after discharge. After six weeks of the therapy, laboratory test results were detected as follows: hemoglobin: 16.3 g/dL, platelets: 250.103/μL, white blood cell: 6,000 /μL, AST: 20 U/L, ALT: 25 U/L, CRP: 4 mg/ dL, sedimentation: 12 mm/h, ferritin: 250 ng/ml and standard tube agglutination test: 1/320. After that, the treatment was stopped due to the absence of complaints from the patient.
Discussion
Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder characterized by an intense hyperimmune response and uncontrolled release of inflammatory cytokines. In addition, it involves hyperactivation of macrophages, cytotoxic T lymphocytes and natural killer (NK) cells, leading to multiorgan failure and, often, death. HLH could be primarily triggered by genetic etiology or malignancy, secondarily associated with autoimmune diseases and infections [5, 6]. Brucellosis infection could rarely lead to hemophagocytosis syndrome. Brucellosis is the most common zoonotic disease around the world and over 500,000 new cases of brucellosis are reported each year. Brucellosis is an endemic disease, especially in the middle east
and southeast of the Anatolian region of Türkiye. The main symptoms of brucellosis are fever, myalgia, hepatosplenomegaly,
diarrhea, lymphadenopathy, arthralgia and arthritis, and the most common complaint is fever. Hepatosplenomegaly, anemia, and leukopenia are frequently associated with acute brucellosis. The incidence of pancytopenia in brucellosis patients are reported between 3-21% . In the reported case, the symptoms of the patient are high fever, diarrhea, and headache. The patient had elevated levels of bicytopenia, massive HSM, ferritin, AST and ALT. Although HLH is not usually easy to diagnose, the main symptoms in the patient were fever, cytopenia, hepatosplenomegaly and hemophagocytosis [7]. Hemophagocytized histiocytes should be observed in bone marrow, spleen, and lymph node. Since biopsy of the spleen and lymph nodes is an invasive procedure, the bone marrow biopsy was performed. In this case, hemophagocytosis was demonstrated in the bone marrow cellular elements [2, 3]. The diagnosis of Brucella species can be mostly made by serological tests and molecular methods due to the low isolation rate in blood cultures. Serological diagnosis of Brucellosis is based on screening test with Rose Bengal (RB) and detection of antibody titers measured by a standard serum tube agglutination (STA) test. In addition to that, confirmation with the Brucella Coombs gel test is necessary since false negative results may be obtained with the STA test. Bone marrow and blood cultures of Brucella cases have been reported to be positive in 82.5- 92% and 45-70% of the patients, respectively. Initial results of RB, STA, and Coombs tests were negative in the reported case, but they were detected to be positive on the tenth day of the treatment. Brucella melitensis growth in the blood and bone marrow cultures was detected on the seventh day of incubation [7]. Hemophagocytic syndrome could be very severe and mortal. Bleeding caused by severe thrombocytopenia or infections due to neutropenia can cause mortality. Therefore, patients with hemophagocytic syndrome must be quickly diagnosed and necessary treatments should be initiated immediately. If there is no significant clinical improvement in patients in spite of the treatment of the disease, additional supportive treatment and IVIG should be provided to the patients [1].
Conclusion
HLH associated with brucellosis is an inflammatory disease that frequently affects children. However, it is increasingly being diagnosed in adults. Brucellosis in endemic regions should be considered as a predisposing infection in cases with HLH symptoms such as prolonged fever, splenomegaly, cytopenia and high ferritin levels, and must be appropriately treated. IVIG, steroid or immunosuppressive agents may be used in the treatment if clinical and laboratory findings of the patients do not improve due to hemophagocytosis syndrome.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Yildiz H, Van Den Neste E, Defour JP, Danse E, Yombi JC. Adult haemophagocytic
lymphohistiocytosis: a review, QJM: An International Journal of Medicine. 2022;115 (4) 205-13.
2. Zhang Q, Zhu L, Zhu J, Yang X, Zhou D, Zheng Y, et al. Adult onset haemophagocytic lymphohistiocytosis prognosis is affected by underlying disease: analysis of a single-institution series of 174 patients. Swiss Med Wkly. 2018; 148:14641.
3. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7
years. Br J Haematol. 2016; 172(3):412-9.
4. Öner SZ, Türkoğlu E. Seroprevalence of Brucellosis from a Region Where Low Endemicity is Expected. Med J West Black Sea. 2020;4(1):18-23.
5. Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2018;24;13:27-49.
6. Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev. 2016;30(6)411-20.
7. Kerget F, Kerget B, Çelik N, İba Yılmaz S. Specific Tests and Inflammatory Biomarkers in the Evaluation of Brucellosis Disease. Mikrobiyol Bul. 2021;55(2):113-24.
Download attachments: 10.4328.ACAM.21710
Filiz Kurklu Bozkır, Seval Sönmez Yildirim, Rafiye Ciftciler. Brucellosis case presenting with bicytopenia due to hemophagocytic syndrome. Ann Clin Anal Med 2025;16(Suppl 2):S105-107
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
A case of langerhans cell histiocytosis in the frontal bone: Surgical and clinical perspectives
Ekin Lal Akat 1, Beyza Öztürk 1, Gözde Erçetin 1, Ahmet Tolgay Akıncı 2
1 Medical Student, Faculty of Medicine, 2 Department of Neurosurgery, Trakya University, Edirne, Turkey
DOI: 10.4328/ACAM.22344 Received: 2024-07-29 Accepted: 2024-10-03 Published Online: 2024-11-04 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S108-111
Corresponding Author: Ekin Lal Akat, Faculty of Medicine, Trakya University, Edirne, Turkey. E-mail: ekinlal.akat@icloud.com P: +90 543 851 21 44 Corresponding Author ORCID ID: https://orcid.org/0000-0002-8978-6649
Other Authors ORCID ID: Beyza Öztürk, https://orcid.org/0009-0004-7822-8109 . Gözde Erçetin, https://orcid.org/0009-0002-4095-8822 . Ahmet Tolgay Akinci, https://orcid.org/ 0000-0002-9937-076X
This case report details the diagnosis and treatment of Langerhans Cell Histiocytosis (LCH) in the frontal bone of a 14-year-old male. The patient presented with a palpable swelling on the forehead, and subsequent imaging studies revealed significant bony destruction. Histopathological examination confirmed the diagnosis of LCH. A surgical resection was successfully performed, resulting in symptom resolution without recurrence at a six-month follow-up. This case points to the importance of considering LCH in differential diagnoses of cranial lesions in children, highlighting the successful role of surgical approaches in managing localized LCH. Multidisciplinary collaboration was crucial for early diagnosis and optimal outcomes in this uncommon pediatric condition.
Keywords: Eosinophilic Granuloma, Frontal Bone, Langerhans Cell Histiocytosis, Pediatrics
Introduction
Langerhans Cell Histiocytosis (LCH) is a medical condition that was first identified in the early 1900s as case reports and is defined as the accumulation of aberrant proliferation of Langerhans cells within several tissues and organs and is characterized by granulomatous lesions [1, 2]. Kapukaya et al. proposes that LCH acts as a localized form of eosinophilic granuloma in the bone tissue. No genetic research proves that LCH may be a genetic disorder. Since some types of LCH have a terrible prognosis, it is classified as a neoplasm. However, current ideas focus on whether LCH is immunologic [2]. It is possible for the disease to affect one organ or multiple systems.
LCH is sporadic, with an incidence ranging from 2 to 9 cases per million children under the age of 15, with this being the most common age group, while the peak incidence belongs to children aged 1 to 3 years. In adults, LCH is extremely rare [3].
This case report illustrates a rare manifestation of LCH in the frontal bone of a 14-year-old male, a presentation seldom reported in medical literature, thereby offering valuable insights focusing on the diagnostic obstacles and efficient management methods for pediatric LCH cases, especially those involving atypical cranial sites.
Case Report
A 14-year-old male patient applied to our outpatient clinic complaining of “swelling on the right side of the forehead and pain” that had been present for one month. There was nothing special in his medical history other than inguinal hernia and tonsillectomy surgeries. On physical examination, there was a soft swelling on the forehead’s skin, positioned slightly off-center from the midline (Figure 1).
No pathological findings were detected in the neurological examination. In the cranial MRI and CT examinations performed, significant destruction is caused in the external table just to the right of the midline in the frontal bone, which is assumed to mainly come from the diploe distance. Its dimensions were measured as 19 x 11 mm in the axial plane, showing iso-hyperintense in the T2-weighted series (Figure 2a) and heterogeneous contrast enhancement in the post-contrast series (Figure 2b). The lesion was initially evaluated as Langerhans cell histiocytosis. A surgical resection under general anesthesia via a linear incision was planned and carried out (Figures 3a, 3b, 3c, and 3d). The differential diagnosis for cranial lesions in pediatric patients includes a variety of conditions, each with distinct imaging and histopathological features. In this case, the differential included osteomyelitis, and metastatic disease, among others.
Osteomyelitis was initially considered due to a bone lesion with associated swelling. However, this was ruled out based on the absence of elevated inflammatory markers typically seen in infection, such as C-reactive protein and erythrocyte sedimentation rate, and the lack of fever or other symptoms indicating systemic infection.
Metastatic disease was also considered due to the destructive nature of the lesion. The lack of other systemic symptoms often associated with cancer, such as weight loss or night sweats, along with a normal complete blood count, helped to exclude this diagnosis.
The final diagnosis of Langerhans Cell Histiocytosis was supported by the radiologic finding of a lesion with mixed lytic and sclerotic features, predominantly arising from the diploic space—typical of LCH. Histopathological findings confirmed the existence of Langerhans cells with characteristic CD1a and S-100 protein-positive staining, which are definitive for LCH and not observed in the other conditions considered.
The pathological examination was compatible with Langerhans cell histiocytosis. A follow-up MRI in the sixth month showed no residual or recurrent lesion (Figure 2c), and the patient was free of any symptoms.
Informed Consent
Informed consent was obtained from patient.
Discussion
The skull is the most affected part of the skeleton in LCH cases. In our case, the frontal bone, which is one of the most frequent involvements in LCH cases, was affected. The parietal and temporal bones constitute the rest of the majority. In Türkiye, one of the most detailed analyses of LCH cases is an evaluation of 217 patients presented by Yağcı et al. In this retrospective analysis, the most frequently affected bone was the skull, as expected based on other involvements reported so far [4]. A typical LCH lesion presents as a soft palpable cyst and manifests with pain [3]. Similarly, in our case, the patient’s main complaints were swelling and pain.
Besides the clinical presentation, histological assessments are needed for a differential diagnosis [5]. Further, radiological investigations have an essential role in LCH cases, particularly in bones, as in this case [6]. However, to diagnose LCH, radiological imaging may be insufficient since LCH may show features similar to other etiologies, such as multiple myeloma. Therefore, a biopsy is essential to diagnose specific lesions [7]. The LCH cases with frontal bone involvement do not carry a risk for central nervous system involvement, thus surgical treatment is generally preferable [3]. Curettage operations might be performed for lesions smaller than 2 cm [8]. Treatment planning depends on the disease’s severity and the organ involved [7]. Because of these factors and the possibility of spontaneous remission, there is currently no specific or standardized treatment protocol for this disease. [2].
In our case, the lesion’s dimensions were measured as 19 x 11 mm. There was a one-month continuance, and as a result of the cranial MRI and CT examinations, a surgical resection under general anesthesia was performed. Then, the lesion was initially evaluated as LCH, and this evaluation became absolute with the biopsy.
Conclusion
This case report highlights a presentation of Langerhans Cell Histiocytosis in the frontal bone of a young patient, emphasizing the challenges associated with diagnosing and treating this uncommon disease. The successful surgical resection of the lesion, without recurrence at a six-month follow-up, demonstrates the effectiveness of prompt and precise surgical intervention in localized LCH cases. Furthermore, this case underscores the importance of considering LCH in diagnosing bone lesions in children and adolescents, mainly when presenting as palpable cyst-like swellings in the skull.
Multidisciplinary collaboration and a high index of suspicion are crucial for early diagnosis and optimal management of LCH, aiming to prevent potential complications and improve patient outcomes. Our experience suggests that surgical intervention, complemented by thorough radiological and histopathological evaluation, remains a cornerstone in managing localised LCH, contributing positively to patient prognosis. Future studies and case reports are essential to enhance our understanding of LCH, refine diagnostic criteria, and improve therapeutic strategies for this complex condition.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856–68.
2. Kapukaya A. Langerhans-hücreli histiyositoz [Langerhans-cell histiocytosis]. TOTBID Derg. 2013;12(6):547–56.
3. Leung AK, Lam JM, Leong KF. Childhood Langerhans cell histiocytosis: A disease with many faces. World J Pediatr. 2019;15(6):536–45.
4. Yağcı B, Varan A, Çağlar M, Söylemezoğlu F, Sungur A, Orhan D, et al. Langerhans cell histiocytosis: Retrospective analysis of 217 cases in a single center. Pediatr Hematol Oncol. 2008;25(5):399–408.
5. Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children. J Am Acad Dermatol. 2018;78(6):1047–56.
6. Tawashi K, Khattab K. Langerhans cell histiocytosis of the frontal bone with unexpected manifestations: Rare case report. Int J Surg Case Rep. 2023;109:108580.
7. Mo JT, Darrow MA, Sharma JD. Langerhans cell histiocytosis with aneurysmal bone cyst-like changes: A case-based literature review. Childs Nerv Syst. 2023;39(11):3057–64.
8. Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2012;60(2):175–84.
Download attachments: 10.4328.ACAM.22344
Ekin Lal Akat, Beyza Öztürk, Gözde Erçetin, Ahmet Tolgay Akıncı. A case of langerhans cell histiocytosis in the frontal bone: Surgical and clinical perspectives.Ann Clin Anal Med 2025;16(Suppl 2):S108-111
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Anesthesia management in patients with dundar syndrome: A case report
Ferah Sarica 1, Ali Akdogan 2
1 Department of Anesthesiology and Critical Care, Acibadem Kayseri Hospital, Kayseri, 2 Department of Anesthesiology and Critical Care, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkiye
DOI: 10.4328/ACAM.22369 Received: 2024-08-14 Accepted: 2024-09-24 Published Online: 2024-11-27 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S112-114
Corresponding Author: Ali Akdogan, Department of Anesthesiology and Critical Care, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkiye. E-mail: draliakdogan@yahoo.com P: +90 462 377 57 41 Corresponding Author ORCID ID: https://orcid.org/0000-0001-7592-3844
Other Authors ORCID ID: Ferah Sarica, https://orcid.org/0000-0002-7327-1974
In patients diagnosed with Dundar syndrome, the dysmorphic appearance of the face, muscle hypotension and kyphoscoliosis make anesthesia management important. Pre-operative examination of patients is important in terms of accompanying diseases, necessary consultations and required examinations. The pre-surgical anesthesiologist should evaluate these findings in advance, which may lead to difficult mask ventilation and/or difficult intubation, and determine optimal airway management.
Keywords: Dundar Syndrome, Difficult Intubation, Anesthesia, Difficult Mask Ventilation
Introduction
Dündar syndrome was first described in 1997 by Dundar and his colleagues [1]. This syndrome is an autosomal recessive disease characterized by characteristics such as adhesion adduction of the thumb, crushed legs, kyphoscoliosis, joint instability, muscle hypotension, preferred front chamber retention, dysmorphic facial appearance [2, 3]. Heart, intestine, and kidney seizures can also be observed. In this case, we wanted to present preoperative evaluation of the Dundar syndrome patient and difficult airway management.
Case Report
A 19-year-old woman diagnosed with Dundar’s syndrome, ASA-II class, was scheduled for rhinoplasty. During the preoperative examination, the patient was to have had multiple operations due to thumb-clup foot and retinal detachment due to her current illness, and had not encountered a complication. Although it was rare due to the characteristics of the syndrome, the patient was consulted with the relevant departments for the cause of the heart and kidney retention, and no additional problem was found. In the preoperative anesthesia examination, the Mallampati score was 2 for micrognathia, hand deformities and airway examination (Figure 1). The patient’s preoperative values were normal, and the patient was taken to the hospital with adequate periods of starvation. All the preparations were made, including videolaryngoscope, stylet, varied-dimensional endotracheal tubes and supraglottic airway devices (SGAs), considering it could be a difficult airway, difficult intubation before being taken to the operating room. Informed consent was obtained from the patient. The monitored patient’s peripheral saturation in room air was measured at 99%, pulse 80 bpm, and blood pressure 125/80 mmHg. After 3 minutes of 100% preoxygenization for general anesthesia induction, the patient was administered 1mg midazolam, 1mcg/kg fentanyl, 20mg arithmal, 2.5mg/kg propofol and 0.6 mg/kg rocuronium. The patient, who was unable to be injected with a Macintosh laryngoscope after an appropriate muscle relaxation period was expected, was initiated in a second trial with Mccoy and a difficult intubation bougie. Anesthesia was administered with an infusion of 40% oxygen, 60% air, sevoflurane (2 MAC) and remifentanil 0.3mcg/kg/min. After intubation, 1mg/kg methylprednisolone and 50mg pantoprazole were also administered intravenously. The patient, whose surgery duration was 1 hour and 40 minutes, was given15 mg/kg paracetamol and 1mg/kg tramadol intravenously as an analgesic and also an antiemetic just before waking up. 2 mg/kg sugammadex was administered for antagonism of neuromuscular blockers. When the patient’s vital signs was stable, spontaneous breathing, and sufficient vigilance, the patient was taken to the postoperative care unit. The patient, who was followed in the recovery unit for 20 minutes, was sent to hospital room when Aldrete scored 9.
Discussion
In patients diagnosed with Dündar syndrome, the dysmorphic appearance of the face, muscle hypotension and kyphoscoliosis make anesthesia management important. Pre-operative examination of patients is important in terms of accompanying diseases, necessary consultations and required examinations. Because Dundar’s syndrome is a very rare syndrome, there are few publications in the literature and there is no data on the administration of anesthesia. So we decided to apply general anesthesia based on the patient’s clinical condition and surgical procedure. In these patients, characteristic anomalies in the craniofascial region seen in these patients include small face and micrognathia, which affect the patient’s mask ventilation and intubation.The patient’s position may be difficult due to bone deformities, changes associated with kyphoscoliosis. The pre-surgical anesthesiologist should evaluate these findings in advance, which may lead to difficult mask ventilation and/or difficult intubation, and determine optimal airway management. Our patient had difficult intubation preparation because of narrow mouth, micrognathy, limited neck extension. In such patients with difficult airways, the success of intubation is proportional to the experience of the practising anesthesiologist. The patient is awakened by taking the necessary precautions and providing a good analgesia. Preparations must be made for a possible re-intubation, and alternative aircraft equipment must be provided.
It should not be forgotten that patients with Dündar syndrome have difficult airway, and the pre-surgical evaluation of the possible difficulties in the management of anesthesia should be complete and detailed. Alternative airway equipment must be available for difficult airway management.Preparation in patients with suspected difficult airways improves the success of intubation, while also reducing possible complications. Therefore, careful perioperative monitoring is required for the early detection and management of any possible complications that may occur in these patients.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Dundar M, Demiryilmaz F, Demiryilmaz I, Kumandas S, Erkilic K, Kendirci M, et al. An autosomal recessive adducted thumb-club foot syndrome observed in Turkish cousins. Clin Genet. 1997;51(1):61–64.
2. Uzak AS, Fryns JP, Dundar M. Syndromes presenting adducted thumb with/without clubfoot and Dundar syndrome. Genet Couns. 2014;25(2):159-69.
3. Dündar M, Müller T, Zhang Q, Pan J, Steinmann B, Vodopiutz J, et al. Loss of dermatan-4-sulfotransferase 1 function results in adducted thumb-clubfoot syndrome. Am J Hum Genet. 2009;85(6):873-882.
Download attachments: 10.4328.ACAM.22369
Ferah Sarıca, Ali Akdogan. Anesthesia management in patients with dundar syndrome: A case report. Ann Clin Anal Med 2025;16(Suppl 2):S112-114
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
COVID-19 associated pulmonary aspergillosis
Mirkan Bulğak, Tuna Demirdal
Department of Microbiology, Izmir Katip Celebi University, Ataturk Research and Training Hopital, Izmir, Turkey
DOI: 10.4328/ACAM.22419 Received: 2024-09-24 Accepted: 2024-11-04 Published Online: 2024-11-18 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S115-117
Corresponding Author: Mirkan Bulğak, Department of Microbiology, Izmir Katip Celebi University, Ataturk Research and Training Hopital, Izmir, Turkey. E-mail: mirkanbulgak@gmail.com P: +90 532 792 31 79 Corresponding Author ORCID ID: https://orcid.org/0000-0003-3020-9414
Other Author ORCID ID: Tuna Demirdal, https://orcid.org/0000-0002-9046-5666
During the COVID-19 pandemic, invasive fungal infections, particularly pulmonary aspergillosis, became a significant health issue in immunocompromised patients. This case report discusses a patient diagnosed with hairy cell leukemia who developed neutropenia following cladribine chemotherapy and subsequently experienced a complicated case of invasive pulmonary aspergillosis associated with COVID-19. The treatment process and outcomes provide important insights into the management of COVID-19-associated invasive pulmonary aspergillosis (CAPA). The patient was diagnosed with invasive aspergillosis during COVID-19 treatment and achieved a successful recovery with voriconazole therapy.
Keywords: COVID-19, Pulmonary Aspergillosis, Voriconazole, Neutropenia, Hairy Cell Leukemia, CAPA
Introduction
Pulmonary aspergillosis is known as a serious opportunistic infection in immunocompromised patients, and a significant increase in the incidence of this infection has been observed during the COVID-19 pandemic. The incidence of invasive pulmonary aspergillosis in COVID-19 patients has been reported to vary between 19.6% and 33.3%, and the mortality rate of this disease can be as high as 64.7% [1, 2]. In this case report, we present a patient with a diagnosis of Hairy cell leukemia who developed invasive pulmonary aspergillosis during COVID-19 infection, as we believe that sharing clinical experience may be important. Informed consent was obtained from the patient.
Case Report
A 41-year-old male patient diagnosed with hairy cell leukemia was admitted to our hospital with the diagnosis of neutropenic fever that occurred after cladribine chemotherapy. The patient was empirically started on piperacillin-tazobactam. However, when the patient’s infective markers showed progression, and the fever continued, the treatment was changed to meropenem+teicoplanin. No growth was observed in the cultures. Clinical and laboratory responses were observed in the patient from the third day of the new treatment combination.
G-CSF treatment was given upon the development of pancytopenia. Endoscopy was planned for the patient, who also complained of difficulty swallowing, with suspicion of candida esophagitis, and the COVID-19 PCR test taken before the procedure resulted positive. Fluconazole treatment was started for esophagitis. No COVID-19 pneumonic infiltration was detected in the thorax CT. On the 8th day of COVID-19 treatment, the patient experienced respiratory distress and an increase in infection markers (procalcitonin, CRP), and 250 mg methylprednisolone (3 days) was added to his treatment.
On the 9th day of COVID-19 treatment, thoracic CT revealed consolidation areas consistent with invasive aspergillosis. A sputum culture and galactomannan antigen test sample were taken from the patient. After a positive aspergillosis finding on CT, a sputum culture was sent in the morning on an empty stomach for three consecutive days. The samples taken were first examined under a direct microscope with calcofluor white-KOH. Then, they were planted on abuse dextrose agar. There was no growth in all three cultures during the 1-month incubation period. Galactomannan antigen was found positive. The patient was started on voriconazole treatment, and a decrease in respiratory distress and oxygen requirement was observed. In addition, the patient’s neutropenic condition improved. Upon regression of infectious markers, the patient’s meropenem+teicoplanin treatment was discontinued on the 24th day.
The patient was discharged with oral voriconazole treatment. Voriconazole was initially started at 400 mg PO twice daily and then continued at 200 mg po twice daily. In the control thorax CT performed during the 1st month of voriconazole treatment, significant regression of infiltrations was observed. It was decided to continue the treatment until the infiltration areas completely disappeared. In the 12th week of treatment, the infiltration areas completely disappeared, and the treatment was terminated.
Discussion
During the COVID-19 pandemic, there has been a significant increase in the incidence of invasive fungal infections (IFE), especially in immunocompromised patients receiving treatment in intensive care units. One of the most striking of these infections is invasive pulmonary aspergillosis (IPA). Fungal events accompanying respiratory tract infections are a serious cause of complications, especially in immunocompromised COVID-19 patients. This condition has been included in the literature as COVID-19-associated pulmonary aspergillosis (CAPA). The effect of SARS CoV-2 on the immune system and immunosuppressive treatments increase the risk of developing such invasive infections [1, 3]. In our case, neutropenia developing after cladribine chemotherapy and COVID-19 together paved the way for pulmonary aspergillosis.
In addition, complications such as acute respiratory distress syndrome (ARDS) caused by COVID-19 infection increase the risk of developing pulmonary aspergillosis. Therefore, the presence of invasive fungal infections in respiratory tract infections complicated by COVID-19 should not be ignored. In high-risk patient groups, additional tests should be performed with a more aggressive approach for the diagnosis of CAPA, and prophylaxis or treatment should be started early. Especially in cases where the galactomannan test and CT findings are positive, antifungal treatment should be started immediately [4, 5]. In our case, when the galactomannan antigen test was taken immediately after the aspergillosis-compatible CT finding was observed and it was determined positive, voriconazole treatment was started without delay. In this case, the development of CAPA in a patient receiving chemotherapy with the diagnosis of Hairy cell leukemia was investigated. Neutropenia in these patients constitutes an important risk factor for fungal infections. Clinical recognition of pulmonary aspergillosis developing during COVID-19 infection may be difficult because it may present with similar respiratory symptoms to COVID-19. Therefore, high clinical suspicion and early diagnostic methods are critical for the success of treatment. Histopathological examination, sputum culture, bronchoalveolar lavage (BAL) culture, aspergillus PCR, serum galactomannan, BAL galactomannan, direct radiography, and computed tomography are used in the diagnosis of CAPA [6]. In our case, histopathological examination could not be performed, and aspergillus spp did not grow in the sputum culture, but the diagnosis was made with high clinical suspicion, imaging compatible with aspergillosis and galactomannan antigen positivity.
Voriconazole and isavuconazole are the first-line antifungal agents used in CAPA treatment. However, in cases of voriconazole resistance, side effects, and drug interactions, liposomal amphotericin B is the first drug to be used as an alternative to these drugs. Alternative second-line options are posaconazole or echinocandins. Echinocandins should not be used as monotherapy if other options remain, but they can be used as salvage therapy. In this case, a successful result was obtained with early antifungal treatment. Voriconazole treatment plays an important role in reducing mortality in CAPA cases. Voriconazole should be given as a loading dose of 6 mg/kg twice daily on the first day, followed by a maintenance dose of 4 mg/kg twice daily, and liposomal amphotericin B should be administered at a dose of 3 mg/kg daily. Although the treatment period is stated as 6-12 weeks, the treatment period may be longer in immunocompromised patients, depending on the patient’s clinic, radiological findings, and galactomannan antigen monitoring [7].
Conclusion
Pulmonary aspergillosis is more common in patients with COVID-19 infection, especially in the presence of complications such as immunosuppressive conditions or ARDS, and has high mortality rates. Voriconazole is the first-line agent in the treatment of CAPA. Caution should be exercised in terms of pulmonary aspergillosis in COVID-19 patients, and early antifungal therapy should be initiated if necessary.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Verweij PE, Gangneux JP, Bassetti M, Brüggemann RJM, Cornely OA, Koehler P, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020;1(2):e53-e55.
2. Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. 2021;73(11):e3606-e3614.
3. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. J Infect. 2020;81(2):266-275.
4. Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534.
5. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit. Clin Infect Dis. 2021;73(7):e1634-e1644.
6. Tsotsolis S, Kotoulas SC, Lavrentieva A. Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape. Adv Respir Med. 2023;91(3):185-202.
7. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-e162.
Download attachments: 10.4328.ACAM.22419
Mirkan Bulğak, Tuna Demirdal. COVID-19 associated pulmonary aspergillosis.Ann Clin Anal Med 2025;16(Suppl 2):S115-117
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Multidisciplinary approach to appendiceal mucoceles: A case presentation
Arslan Hasan Kocamaz 1, Ömer Kişi 2, Abdulkadir Çelik 3, Celalettin Vatansev 2
1 Department of General Surgery, Kayseri State Hospital, Kayseri, 2 Department of General Surgery, School of Medicine, Necmettin Erbakan University, Konya, 3 Department of General Surgery, Gaziantep Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
DOI: 10.4328/ACAM.22424 Received: 2024-09-27 Accepted: 2024-11-04 Published Online: 2024-11-20 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S118-120
Corresponding Author: Arslan Hasan Kocamaz, Department of General Surgery, Kayseri State Hospital, Kayseri, Turkey. E-mail: md.ahkocamaz@gmail.com P: +90 530 967 64 11 Corresponding Author ORCID ID: https://orcid.org/0000-0002-5257-9611
Other Authors ORCID ID: Ömer Kişi, https://orcid.org/0000-0001-8606-2453 . Abdulkadir Çelik, https://orcid.org/0000-0002-5537-7791
Celalettin Vatansev, https://orcid.org/0000-0002-0094-1703
This study was approved by the Ethics Committee of Necmettin Erbakan University for Non-Drug and Non-Medical Device Research (Date: 2024-10-18, No: 2024/5255)
Mucosal appendicitis is a rare condition marked by dilation of the appendix and accumulation of mucus, often discovered incidentally during surgical interventions for appendicitis. This article presents a case of appendiceal mucoceles in a 54-year-old female patient with a history of diabetes and asthma, who was diagnosed following abdominal imaging that indicated appendiceal involvement. Surgical exploration revealed an enlarged appendix, leading to a right hemicolectomy. Histopathological analysis confirmed poorly differentiated mucinous neoplasia, with clear surgical margins, suggesting a favorable prognosis for recovery. The case underscores the importance of early diagnosis and surgical treatment in managing appendiceal mucinous neoplasms, as timely intervention can mitigate the risks of severe complications, such as pseudomyxoma peritonei. Through this case, we emphasize the necessity for a multidisciplinary approach to enhance diagnostic and therapeutic outcomes in similar presentations.
Keywords: Appendiceal Mucoceles, Mucosal Appendicitis, Surgical Intervention
Introduction
Mucosal appendicitis is a rare pathological condition characterized by dilation of the appendix and accumulation of mucus. Typically, it is discovered incidentally, and its symptoms are quite nonspecific. We can divide appendiceal mucinous tumors into two main groups: benign and malignant, with the latter potentially leading to serious complications. Rokitansky first described the appendiceal mucosa in 1842, according to reports [1]. Patients typically discover this pathology during surgery with a preliminary diagnosis of appendicitis, and if untreated, it can result in serious complications, such as pseudomyxoma peritonei [2]. Appendiceal mucinous lesions are divided into four main subtypes: simple mucinous, hyperplastic mucinous, mucinous cystadenoma, and mucinous cystadenocarcinoma [3]. This classification is critical for determining the prognosis of the disease. If mucinous cystadenocarcinoma ruptures, the mucin content can spread into the peritoneum, leading to pseudomyxoma peritonei. This situation can significantly reduce the patient’s quality of life and may lead to mortality [4]. Appendiceal mucinous neoplasm is treated surgically, and depending on the type of disease, an appendectomy or more extensive resections may be required [5]. Early diagnosis and surgical intervention prevent the disease from spreading and reduce the risk of complications. The post-surgical histopathological evaluation makes a definitive diagnosis. This article presents a case with appendiceal mucoceles and discusses the diagnostic and treatment process by comparing it with similar cases in the literature.
Case Report
A 54-year-old female patient presented to the emergency department with complaints of abdominal pain along with a known history of diabetes mellitus and asthma. The patient was using oral antidiabetic treatment and an inhaler. She has a history of three births, one of which was by cesarean section, and underwent a total thyroidectomy operation 10 years ago due to a goiter diagnosis. The emergency department’s abdominal ultrasound revealed a cyst measuring approximately 10×5 cm in the left adnexal region, prompting a referral to the obstetrics and gynecology department for further evaluation. The obstetrics and gynecology clinic conducted a detailed evaluation and determined that the cyst might not have originated from the ovary or fallopian tube, leading to the planning of an abdominal magnetic resonance (MR) examination as an advanced imaging method. The MRI result indicated a preliminary diagnosis of appendicitis with mucosal involvement (Figure 1). After completing the necessary preoperative preparations, we transferred the patient to the general surgery clinic for elective surgery. During the operation, the surgical team detected an enlarged appendix measuring approximately 11×7 cm and confirmed the diagnosis of appendiceal mucosa. Given the severity of the pathological findings, we performed a right hemicolectomy (Figure 2). Following the operation, the patient demonstrated a smooth recovery and was discharged on the 5th postoperative day in good health. The histopathological examination of the excised appendiceal tissue led to the diagnosis of poorly differentiated mucinous neoplasia in the appendix. The surgeon reported clear surgical margins and successfully discharged the patient without any findings of malignancy spread.
Ethical Approval
This study was approved by the Ethics Committee of Necmettin Erbakan University for Non-Drug and Non-Medical Device Research (Date: 2024-10-18, No: 2024/5255).
Discussion
Mucosal appendicitis is a rare pathological condition characterized by dilation of the appendix and accumulation of mucus. Clinical symptoms are generally nonspecific, and most patients may be asymptomatic. Surgical intervention usually detects and diagnoses appendiceal mucosal neoplasms incidentally. However, for patients presenting with symptoms such as abdominal pain and an abdominal mass, it is an important pathology that should be considered in the differential diagnosis [1]. The patient initially presented to the obstetrics and gynecology clinic with nonspecific abdominal pain, and the ultrasound results suggested a mass originating from the ovary or adnexal region. However, the use of more advanced imaging methods revealed that the cyst originated from the appendix and developed into a mucosal cyst.
Four main histological categories divide the mucoceles of the appendix: simple mucocele, hyperplastic mucocele, mucinous cystadenoma, and mucinous cystadenocarcinoma [2]. This classification is critical for understanding the prognosis of the disease. Simple and hyperplastic mucosal lesions are generally benign, and the prognosis after treatment is good. However, mucinous cystadenomas and mucinous cystadenocarcinomas can turn cancerous, and when they rupture, they can cause serious problems like pseudomyxoma peritonei [3]. In our case, the histopathological examination revealed poorly differentiated mucinous neoplasia, but it was reported that the surgical margins were clear. This finding suggests that the tumor has a low potential for spread and that surgical treatment is adequate.
Surgery is the primary method of diagnosing appendiceal mucinous neoplasm. However, during the preoperative period, abdominal imaging methods can contribute to the diagnosis. Ultrasound is generally the first imaging method used, but it can be difficult to differentiate appendiceal mucoceles from ovarian cysts or other adnexal lesions [4]. In our case, the first ultrasound detected a cyst in the adnexal region, leading to her referral to the obstetrics and gynecology clinic. However, the advanced imaging method of magnetic resonance (MR) examination accurately identified the appendiceal mucosa. In these cases, MRI plays an important role in diagnosis because it provides high-resolution images [5]. It particularly provides an advantage over other imaging methods in evaluating the size, location, and relationship of the mucosa with surrounding tissues.
Surgical treatment is the primary approach to managing appendiceal mucoceles. The surgical approach may vary depending on the size, location, and malignancy potential of the mucosal lesion. In simple mucosal cases, an appendectomy may be sufficient, while in cases with malignant potential, a right hemicolectomy or more extensive resections may be necessary [6]. In our case, the large dimensions of the appendix and suspicion of malignancy led us to prefer a right hemicolectomy. This surgical approach aims to ensure the complete removal of the tumor while also minimizing the risk of malignant spread. Often, appendiceal mucosal neoplasms remain asymptomatic, with many patients receiving an incidental diagnosis during imaging studies for other purposes. However, the risk of developing pseudomyxoma peritonei is a significant complication in ruptured mucinous tumors. Pseudomyxoma peritonei occurs when mucus accumulates in the peritoneal cavity following the rupture of an appendiceal mucinous cyst, resulting in a serious clinical picture. People often confuse this condition with peritoneal carcinomatosis, and treating it can be quite challenging [7]. In cases of rupture, surgical treatment often requires aggressive methods such as peritonectomy and hyperthermic chemotherapy. For this reason, the early diagnosis and surgical treatment of appendiceal mucosal lesions are of vital importance.
Histopathological examination plays a critical role in the prognosis and treatment planning of appendiceal mucinous neoplasms. Whether a mucous cyst is benign or malignant, the status of surgical margins and the spread of the cyst to surrounding tissues are determining factors for the patient’s follow-up after treatment [8]. The histopathological examination in our case revealed a diagnosis of poorly differentiated mucinous neoplasia, with clear surgical margins reported. This result indicates that surgical treatment is sufficient, and the patient may not require additional treatment during follow-ups.
Conclusion
Mucosal appendicitis is a rare pathology, but with the appropriate diagnosis and treatment methods, the prognosis is generally good. However, in cases with malignant potential, early surgical intervention and careful monitoring are necessary. In our case, the preoperative period yielded a correct diagnosis, and the appropriate surgical approach led to the patient’s complete recovery and discharge. In such cases, adopting a multidisciplinary approach can enhance the effectiveness of the diagnosis and treatment process.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Stocchi L, Wolff BG, Larson DR, Harrington JR. Surgical treatment of appendiceal mucocele. Arch Surg. 2003;138(6):585-90.
2. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: Clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33(10):1425-39.
3. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27(8):1089-1103.
4. Garg PK, Tewari M, Ahlawat S, Gupta R, Kachroo N, Sood A, et al. Pseudomyxoma peritonei and appendiceal mucinous neoplasms: current diagnostic and therapeutic approaches. World J Gastroenterol. 2021;27(19):2236-2250.
5. Zarif J, Balaji S, Le D, Leong W, Alavi S, Zong Y, et al. Appendiceal mucinous neoplasms: A review of the current literature. J Surg Oncol. 2021;123(5):1105-1115.
6. Cecil TD, O’Connell J, Sugarbaker PH, Misdraji J, Carr NJ. Appendiceal mucinous neoplasms: A contemporary review. Surgical Oncology Clinics of North America. 2020; 29(3):425-444.
7. Lansom J, Alzahrani N, Liauw W, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours. Indian J Surg Oncol. 2016;7(2):166-76.
8. Carr NJ, Cecil TD, Mohamed F, Sugarbaker PH, Stuart OA, Misdraji J, et al. A Consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14-26.
Download attachments: 10.4328.ACAM.22424
Arslan Hasan Kocamaz, Ömer Kişi, Abdulkadir Çelik, Celalettin Vatansev.Multidisciplinary approach to appendiceal mucoceles: A case presentation. Ann Clin Anal Med 2025;16(Suppl 2):S118-120
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Blunt trauma-induced leiomyosarcoma: A case report
Hayriye Şentürk
Department of Family Medicine, Özcan Çalıkuşu Family Health Center No 47, Konya, Turkiye
DOI: 10.4328/ACAM.22686 Received: 2025-04-07 Accepted: 2025-05-12 Published Online: 2025-05-15 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S121-123
Corresponding Author: Hayriye Şentürk, Department of Family Medicine, Özcan Çalıkuşu Family Health Center No 47, Konya, Turkiye. E-mail: hyrybulbul@hotmail.com P: +90 554 632 61 44 Corresponding Author ORCID ID: https://orcid.org/0000-0002-5612-9300
Leiomyosarcoma (LMS) is a rare malignant tumor among soft tissue sarcomas, predominantly occurring in internal organs. Its occurrence in the extremities is even more uncommon. The literature suggests that trauma may contribute to the development of LMS and other soft tissue sarcomas. While there are case reports of trauma-induced LMS, most involve a history of surgical intervention years prior. In this report, we present a case of a 68-year-old female who developed LMS in the extremity within just five months following blunt trauma, along with her clinical course.
Keywords: Soft Tissue Neoplasms, Leiomyosarcoma, Extremities
Introduction
Soft tissue sarcomas are a rare and heterogeneous group of malignant tumors of mesenchymal origin, accounting for less than 1% of malignancies in adults. The histopathological spectrum of sarcomas is broad, as they can arise from various tissues, including striated skeletal and smooth muscle, adipose and fibrous tissue, bone, and cartilage. While most cases lack a clear etiology, factors predisposing to sarcomas include exposure to radiotherapy or chemotherapy, chemical carcinogens, chronic irritation, and lymphedema.
Leiomyosarcoma, which exhibits pure smooth muscle differentiation, is a relatively rare subtype of soft tissue sarcoma, accounting for approximately 5–10% of all cases [1]. It primarily occurs in the uterus, retroperitoneum, intra-abdominal organs, and vascular walls, although it can also be found in bones and soft tissues of the extremities [2].
Reports of leiomyosarcomas developing after musculoskeletal trauma are scarce in the literature, with most cases having a history of one or multiple surgical interventions or occurring after burns. In this report, we present a case of LMS that developed in the upper extremity five months after blunt trauma.
Case Report
A 68-year-old female patient presented with complaints of pain and swelling in her upper thigh five months after a heavy object fell on the area. Physical examination revealed localized tenderness and mild edema, while other systemic examinations were regular. The patient was initially treated with local and systemic nonsteroidal anti-inflammatory drugs (NSAIDs), but as no improvement was observed, she was referred to the orthopedics department.
Plain radiographs showed no bone pathology, but MRI revealed a mass suspected to be malignant, prompting a biopsy. Histopathological examination confirmed LMS. The patient subsequently underwent surgery, radiotherapy, and chemotherapy. Given that LMS most commonly metastasizes to the lungs, a chest imaging study was performed, which suggested metastases in both lungs, leading to further radiotherapy. The patient has been under follow-up for four years without any signs of recurrence.
Ethical Approval
Since this study is a case report, approval from an ethics committee was not sought. Informed consent was obtained from the patient for the publication of this case report.
Discussion
Severe trauma, particularly in burn cases, has been reported as a rare risk factor for neoplasia development. The average latency period between burn injuries and tumor diagnosis has been reported as 31 years [3].
A 2019 review of a 10-year database from an academic tertiary sarcoma center identified six patients with a history of significant musculoskeletal trauma at the site where sarcoma was later developed. Among them, two had osteosarcoma, two had sclerosing rhabdomyosarcoma, and two had malignant peripheral nerve sheath tumors (MPNST) [4]. Five of these patients had undergone multiple surgeries for their injuries. The mean latency period from trauma to sarcoma development was calculated as 19.8 years (range: 10–30 years). While a history of trauma was a standard feature, four out of five cases also had a history of multiple surgical interventions. In contrast, our case involved only blunt trauma, with no prior surgical history. Furthermore, the reported cases primarily included sarcomas other than LMS.
A 1995 case series described various sarcoma types that developed years after surgical interventions. These patients, aged 46–70, were diagnosed with leiomyosarcoma (two cases), angiosarcoma, sclerosing sarcoma, and pleomorphic sarcoma. The mean latency period from surgery to sarcoma development was 23.6 years (range: 8–40 years) [5]. While our patient’s age aligns with the cases reported, the latency period in our case was significantly shorter.
In a 2007 case report, a patient with a history of recurrent nail bed surgery for an ingrown toenail developed an unhealing pyogenic granuloma that persisted for 10 months. A biopsy confirmed LMS, and the patient underwent toe amputation followed by adjuvant chemotherapy [6]. Unlike our case, this patient had a 10-year latency period, yet both cases shared persistent pain and swelling at the trauma site despite treatment.
A 2015 case report described a patient whose forearm was successfully replanted after a traumatic amputation at the distal elbow following a traffic accident. After multiple surgical interventions, a mass developed at the surgical site 24 years later, which was diagnosed as LMS. The patient underwent surgical excision and chemotherapy and remained recurrence-free for three years [7]. Unlike this case, our patient developed LMS within just five months, with no history of multiple surgeries.
Limitation
This case report describes a rare occurrence of leiomyosarcoma developing within a short period after blunt trauma; however, it has several limitations. First, a direct causal relationship between trauma and sarcoma development cannot be definitively established, as the pathophysiology remains unclear. Second, this is a single case report, and more extensive studies are needed to evaluate the potential link between trauma and sarcoma. Third, genetic or molecular analyses were not performed, which could have provided further insights into tumor development. Despite these limitations, this case highlights the need for clinical awareness of soft tissue tumors in patients with persistent post-traumatic symptoms.
Conclusion
As seen in the literature, various sarcomas have been reported following trauma, but most cases involved one or multiple surgical interventions or other substantial etiological factors such as HIV positivity. Additionally, most reported cases exhibited long latency periods before sarcoma development. The distinguishing feature of our case is that the trauma was not surgical but rather due to a heavy object impact, and LMS developed within an exceptionally short period of five months. This case highlights that, although rare, soft tissue tumors such as LMS should be considered in similar cases, particularly in patients with persistent symptoms despite treatment.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Massi D, Beltrami G, Mela MM, Pertici M, Capanna R, and Franchi A. Prognostic factors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases. EJSO. 2024;30(5):565-72.
2. Weeraddana P, Othman H, Elkabbani R, Josey S, Nepal N, Ma E. Pulmonary metastases from primary thigh leiomyosarcoma: a case report and review of the literature. Cureus 2023;15(5):e39562.
3. Eguchi K, Kobayashi K, Honma Y, Ryo E, Sakyo A, Yokoyama K, et al. Clinical and pathological features of second primary neoplasms arising in head and neck reconstructive skin flaps. Sci Re. 2023;13(1):11214.
4. Montgomery C, Park KJ, Gardner JM, Majors I, Nicholas R. Post-traumatic sarcomas: do they exist? J Surg Pathol. 2019;27(7):722-8.
5. Dijkstra MD, Balm AJM, Gregor RT, Hilgers FJM, Lofrus BM. Soft tissue sarcomas of the head and neck associated with surgical trauma. J Laryngol Otol. 1995;109(2):126-9.
6. Engel E, Butler M, Anain J. Leiomyosarcoma of the foot: A case study. J Am Podiatr Med Assoc 2007;97(6):475-9.
7. Pan TJ, Pantanowitz L, Weiss KR. Case Report High-Grade Leiomyosarcoma Arising in a Previously Replanted Limb. Case Rep Oncol Med. 2015;(1):172603.
Download attachments: 10.4328.ACAM.22686
Hayriye Şentürk. Blunt trauma-induced leiomyosarcoma: A case report. Ann Clin Anal Med 2025;16(Suppl 2):S121-123
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Successful treatment of bilateral adrenal Burkitt’s lymphoma in a child at Vietnam National Children’s Hospital: A case report
Lan Ngoc Bui 1, Ai Thi Tran 1, Thach Ngoc Hoang 2, Ngoc Thi Kim Le 3, Hoan Manh Vu 4, Anh Hoai Nguyen 1
1 Oncology Center, Vietnam National Children’s Hospital, 2 Department of Pathology, 3 Department of Imaging Diagnosis, 4 General Surgery Center, Vietnam National Children’s Hospital, Hanoi, Vietnam
DOI: 10.4328/ACAM.22729 Received: 2025-05-06 Accepted: 2025-05-25 Published Online: 2025-05-25 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S124-127
Corresponding Author: Lan Ngoc Bui, Department of Oncology Center, Vietnam National Children’s Hospital, Hanoi, Vietnam. E-mail: ngoclankhoi@gmail.com P: +84 90 410 73 23 Corresponding Author ORCID ID: https://orcid.org/0000-0002-9547-0763
Other Authors ORCID ID: Ai Thi Tran, https://orcid.org/0009-0002-2300-8294 . Thach Ngoc Hoang, https://orcid.org/0000-0002-4747-994X . Ngoc Thi Kim Le, https://orcid.org/0009-0004-1280-5591 . Hoan Manh Vu, https://orcid.org/0009-0006-1279-8795 . Anh Hoai Nguyen, https://orcid.org/0009-0004-3966-3757
This study was approved by the Ethics Committee of National Children’s Hospital (Date: 2023-10-20, No: 1984/BVNTU-HDDD-2023-10)
Bilateral adrenal Burkitt’s lymphoma is sporadic, especially in children. Its prognosis is generally poor in adults, and there is limited data on the pediatric population. We report on the case of a 7-year-old boy who presented with abdominal pain and weight loss. Imaging revealed many lymph nodes around the abdominal aorta, bilateral masses in the adrenal gland, and invading adjacent organs. LDH and acid uric in plasma are moderately elevated. We performed an ultrasound-guided needle core biopsy on his right adrenal gland. Histopathology and immunohistochemistry revealed Burkitt’s lymphoma. His staging assess-ment was stage III. He had been successfully treated with the LMB96 protocol group B, including chemotherapy, residual bilateral adrenal tumor resection, and hormonal replacement. This successful treatment may contribute to current literature about the standard management.
Keywords: Adrenal Gland Neoplasm, Burkitt’s Lymphoma, Children, Vietnam
Introduction
Burkitt’s lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma that typically presents as rapidly growing tumor masses in the abdomen (distal ileum, stomach, cecum, mesentery, and kidney), lymph nodes, jaw or facial bones, and other sites in the lymphatic system. However, primary adrenal lymphoma (PAL) is extremely rare and accounts for < 1% of all non-Hodgkin lymphoma cases in adults, with only sparse reports in children [1].
The most common etiology of bilateral adrenal masses is pheochromocytoma, followed by tuberculosis, PAL, metastases, non-functioning adenoma, and others [2, 3]. Bilateral PAL accounts for 75% of PAL cases, and 61% have adrenal insufficiency[4]. Most patients with adrenal lymphoma are male, and the pathology is diffuse large B-cell non-Hodgkin lymphoma. Clinical manifestations are typically nonspecific and may include abdominal pain, fever, or symptoms of adrenal insufficiency. Imaging often reveals large bilateral adrenal tumors, with an average diameter of around 8 cm in most cases. Prognosis for bilateral PAL has generally been poor in the literature, with early mortality often occurring during chemotherapy. There is currently no standardized treatment of such cases, and management approaches vary mainly as a combination of chemotherapy and surgical resection. Hence, we herein report the successful treatment of a case of bilateral PAL with the LMB96 protocol and hormonal replacement. It aims to enrich the current literature on non-Hodgkin lymphoma in pediatrics and highlights the need for more literature reviews in determining the optimal treatment in such cases.
Case Report
A seven-year-old boy in good physical health was referred to the Vietnam National Children’s Hospital on March 1, 2023, with complaints of a two-month history of significant weight loss and abdominal pain. His medical and family history was unremarkable. Clinical examination detected a palpable mass in the abdomen, but no signs of lymphadenopathy or hypertension.
Laboratory investigations revealed elevated lactate dehydrogenase (LDH) concentration and acid uric levels. However, there were no signs of tumor lysis syndrome with normal levels of calcium, phosphate, potassium, and renal function (Table 1).
CT scan with intravenous contrast was performed and revealed many para-aortic enlarged lymph nodes and bilateral suprarenal hypodense well-defined masses with invasion into the liver and right kidney. The masses measured 120x82x104mm on the right and 96x78x84mm on the left, and both masses showed poor enhancement after intravenous contrast injection. Some small calcifications were within the tumors (Figure 1). The thoracic CT scan did not show any hilar or mediastinal lymphadenopathy. Bilateral adrenal hypodense masses with some small calcifications may suggest several differential diagnoses, including neuroblastoma, adenoma, pheochromocytomas, primary adrenal lymphoma, metastases, or bilateral macronodular adrenal hyperplasia.
Adrenal insufficiency and pheochromocytoma were excluded based on unremarkable medical history, and normal levels of all serum hormones, and urine catecholamine metabolites. Due to the imaging studies showing infiltrative growth of bilateral adrenal glands and lymphadenopathy, an ultrasound-guided needle core biopsy of the right adrenal gland was performed. Histopathological examination revealed Burkitt’s lymphoma, which had a sheet of intermediate-sized cells and a starry sky appearance. Immunohistochemistry examination of the tumor cells was strongly positive with CD20, Ki67 (Figure 2), LCA, CD79a, BCL6, CD10 (not shown) and negative for BCL2, CD3, TdT.
Staging assessment was done with normal bilateral bone marrow aspiration and no involvement of the central nervous system. FISH analysis was performed, and the result surprisingly showed an atypical signal pattern (gain 5’MYC), no MYC rearrangement (Figure 3). Based on these findings and in accordance with the Murphy staging system, the patient was finally diagnosed with stage III Burkitt’s lymphoma. The patient was treated with the FAB/LMB96 protocol, group B, arm B1, for a total of 6 cycles, including: COP, COPADM1, COPADM2, CYM1, CYM2, COPADM3.COP: IV Vincristine 1.0 mg/m2 D1; IV Cyclophosphamide 300mg/m2 D1; po Prednisolone 60mg/m2/day D1 to D7; IT Methotrexate D1; COPADM1 and COPADM2: IV Vincristine 2.0 mg/m2 D1; IV Methotrexate 3000mg/m2 D1; IV Cyclophosphamide 500mg/m2 D2 to D4; IV Doxorubicin 60mg/m2 D2; po Prednisolone 60mg/m2/day D1 to D5; IT Methotrexate D2 and D6; CYM1 and CYM2: IV Methotrexate 3000mg/m2 D1; Cytarabine 100mg/m2 D2 to D6; IT Methotrexate D2 and D7; COPADM3: IV Vincristine 2.0 mg/m2 D1; IV Methotrexate 3000mg/m2 D1; IV Cyclophosphamide 500mg/m2 D2, D3; IV Doxorubicin 60mg/m2 D2; po Prednisolone 60mg/m2/day D1 to D5; IT Methotrexate D2.
Treatment started with the COP regimen on March 13, 2023. The first evaluation on March 22, 2023, showed a significant decrease in the tumor size on both sides: 58x82x78mm on the right and 80x71x62mm on the left. Based on this response, the patient continued chemotherapy with COPADM1. A second assessment was done confirming a complete response, so we continued the chemotherapy regimen, with COPADM2 administered on April 22, 2023, and CYM1 administered on May 23, 2023. However, the third evaluation, following CYM1 on June 21, 2023, CT scan revealed a residual tumor in both adrenal glands. According to the protocol guideline, we operated to remove all the tumors in the bilateral adrenal glands on July 3, 2023. To prevent adrenal insufficiency, we actively prescribed hydrocortisone orally for the patient before, during, and after surgery. No remarkable complication was identified, and the patient recovered well. Histopathology showed near necrosis, with no residual tumor cells on both sides (Figure 2).
The patient received two additional cycles of chemotherapy, including CYM2 on July 11, 2023, and COPADM3 on August 11, 2023, along with oral hydrocortisone for hormonal replacement. During treatment, he experienced many complications, including three episodes of severe febrile neutropenia. We treated him by actively prescribing G-CSF and using antibiotics early based on fever and neutropenia guidelines. Furthermore, the patient faced acute kidney injury due to coordinating amphotericin B and vancomycin febrile neutropenia treatment. We immediately stopped these drugs and gave aggressive supportive care. He is currently recovered with normal organ function. The patient completed chemotherapy in September 2023 and has had regular follow-ups. He has had more than two years of stable disease and with continued hydrocortisone oral replacement. He is in the third year of primary school and healthy enough to play sports with his friends.
Ethical Approval
This study was approved by the Ethics Committee of National Children’s Hospital (Date: 2023-10-20, No: 1984/BVNTU-HDDD-2023-10). Consent was obtained from his parent in this study.
Discussion
Primary adrenal lymphoma is most commonly seen in patients aged 60 – 69 years. It is rare in children, with few cases reported in pediatric literature. To our knowledge, it is the youngest case with bilateral adrenal Burkitt’s lymphoma. Males were more commonly affected than females (male/female: 1.8:1) [4].
The diagnosis of PAL is usually challenging because most of the symptoms are nonspecific. The duration of disease ranged from 2 weeks to 3 months, with a median duration of symptoms of one month. At the time of initial diagnosis, the most common presenting symptoms were B-symptoms, abdominal pain, and fatigue [4]. Individuals may have adrenal insufficiency (AI), which occurs only after the adrenal glands have been destroyed by at least 90% [5]. Vomiting, extreme fatigue, skin discoloration, and hypotension are all signs of adrenal insufficiency. In our case, the patient was a 7-year-old boy with a two-month history of significant weight loss and abdominal pain. Despite bilateral adrenal involvement, he exhibited no clinical signs or symptoms of adrenal insufficiency.
There is no lymphoid tissue in the human adrenal glands, and the exact pathogenesis of primary adrenal lymphoma remains unclear. Many factors have been implicated, including immune dysfunction, mutations in the p53 and c-kit genes, autoimmune-associated infections like Epstein-Barr virus and HIV infections.
In children, neuroblastoma is the most common tumor in the adrenal gland, followed by adrenocortical carcinoma and pheochromocytoma. However, adrenocortical carcinoma and pheochromocytoma are typically hyper-vascular with substantial enhancement after intravenous injection. Primary adrenal lymphoma is less common than neuroblastoma, adrenocortical carcinoma, and pheochromocytoma. On CT scans, primary adrenal lymphoma is characteristically hypodense and poorly enhanced. At diagnosis, PAL masses are commonly large, ranging from 5-8 cm. PAL is not a hyper-vascular tumor with slight to moderate enhancement after intravenous injection. Calcification in lymphoma is rarely seen. In our case, the bilateral adrenal masses were large and poorly enhanced with some small calcifications. At first glance, we considered two possibilities: adrenocortical carcinoma or neuroblastoma infiltrating adjacent organs; however, the histopathology surprisingly confirmed Burkitt’s lymphoma. Notably, the patient’s LDH concentration increases dramatically, which is in accordance with data shown by Wang et al. (2020) [6] (81.1%).
More than 80% of PAL is diffuse large B-cell lymphoma, followed by natural killer (NK)/T-cell lymphoma and peripheral T-cell lymphoma. Bilateral Adrenal Burkitt lymphoma is extremely rare in both children and adults (accounting for 1.1% of all PAL cases). Immunohistochemical analysis revealed that the tumor cells were positive for BCL2 (92%), MYC (70.6%) [6].Our patient’s pathology result was strongly positive for Ki67 (>90%), CD20 (+), BCL6, CD10, CD79a, BCL2 (-). Notably, the FISH analysis showed an atypical signal pattern, a gain of 5’MYC but no MYC amplification. Adult patients with 5’MYC gain showed MYC expression and were often refractory to chemotherapy [7]. However, our patient had a good response to chemotherapy, possibly because we chose an aggressive regimen from the beginning.
The prognosis for PAL is poor, with more than 90% of patients dying within one year after the initial diagnosis. A systematic review of PAL indicated that the 3-, 6-, and 12-month survival rates of PAL were 67%, 46%, and 20% [4]. Another study reported that the estimated 5-year and 10-year OS rates of PAL were 19.17% and 3.33%, respectively. Poor prognostic indicators include older age at diagnosis, large tumor size, adrenal insufficiency at presentation, and elevated LDH levels. Conversely, favorable outcomes are associated with a good initial response to chemotherapy and the patient’s ability to tolerate treatment.
There are several treatment modalities for the management of PAL which including chemotherapy, bilateral adrenalectomy, radiotherapy, and a combination of these approaches. The role of surgery is still controversial and has been associated with poor prognosis. Chemotherapy plays an important role in treatment, which helps increase overall survival and decrease the risk of death (p < 0.05) [6]. The frequently used protocol in adults is CHOP or R-CHOP. Chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the widely recognized strategy for PAL. Studies have shown that compared to traditional CHOP regimens, R-CHOP regimens have higher complete response (76% vs. 56%, p < .005) and higher 2-year OS and PFS rates (57% vs. 38%, p < .001; 70% vs. 57%, p = 007, respectively) [8]. However, our department routinely uses FAB/LMB86 protocol for pediatric Burkitt’s lymphoma, which is why we treated him with chemotherapy, group B (oral prednisone, IV vincristine, cyclophosphamide, doxorubicin, methotrexate, and cranial prophylaxis with IT methotrexate and cytarabine) without rituximab. The third evaluation showed a residual tumor in both adrenal glands, so we operated to remove the tumor and treated and treated the patient with hormonal replacement (hydrocortisone) accordingly. The patient is currently alive and continues to be monitored. He is now in third grade and enjoys good health, actively participating in sports with his friends. The difference between children and adults is intrathecal prophylaxis chemotherapy by methotrexate and cytarabine. 13% of patients with PAL had CNS relapse, and CNS involvement showed a negative impact on long-term prognosis [4]. That is why CNS prophylaxis may be considered in patients with PAL.
Limitation
Due to limited resources country, we could not perform a PET/CT scan at the time of diagnosis for staging assessment. In addition, our case focuses on the unusual disease, so it may be back in the ability to generalize the validity of the study, and publication bias.
Conclusion
In conclusion, we reported the successful treatment of a rare case with bilateral adrenal Burkitt lymphoma in a child with the FAB/LMB96 protocol, including chemotherapy, surgery, and hormonal therapy. Furthermore, it could contribute to current literature about standard management for such cases.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Conflict of interest
The authors declare that there is no conflict of interest.
References
1. Mozos A, Ye H, Chuang WY, Chu JS, Huang WT, Chen HK, et al. Most primary adrenal lymphomas are diffused large B-cell lymphomas with a non-germinal center B-cell phenotype, BCL6 gene rearrangement, and poor prognosis. Blood. 2009;114(5):937-51.
2. Kumar R, Kapoor R, Mahajan A, Dhanlakshmi M, Sharma S, Gupta R, et al. Bilateral adrenal masses in children: a single-center experience. Indian J Urol. 2016;32(2):106-10.
3. Shah A, Bansal D, Marwaha RK, Kumar L, Verma N, Bhalla A, et al. Bilateral adrenal masses in children: A single-center experience. Indian J Pediatr. 2009;76(3):289-93.
4. Kebudi R, Ayan I, Darendeliler E, Tuncer S, Akalay S, Yilmaz M, et al. Primary adrenal lymphoma in children: a report of two cases and review of the literature. Pediatr Hematol Oncol. 2013;30(12):1144-50.
5. Goyal G, Shah MV, Hook CC, Butterfield JH, Tefferi A, Li CY, et al. Clinical features and outcomes of primary adrenal lymphoma: a Mayo Clinic study. Leuk Lymphoma. 2014;55(2):292-6.
6. Zhou Y, Wang H, Li Y, Zhang X, Wu M, Chen L, et al. Primary adrenal lymphoma: a retrospective study of 18 cases. Endocr J. 2020;67(5):595-602.
7. Matsuo T, Ichikawa T, Fujimoto H, Nakano M, Suzuki Y, Takahashi S, et al. Primary adrenal lymphoma: A case report and literature review. Radiol Case Rep. 2023;18(2):272-5.
8. Ichikawa T, Ohtomo K, Araki T, Fujimoto H, Ishikawa T, Matsuo T, et al. Primary adrenal lymphoma: report of four cases and review of the literature. Radiology. 2002;222(3):733-7.
Download attachments: 10.4328.ACAM.22729
Lan Ngoc Bui, Ai Thi Tran, Thach Ngoc Hoang, Ngoc Thi Kim Le, Hoan Manh Vu, Anh Hoai Nguyen. Successful treatment of bilateral adrenal Burkitt’s lymphoma in a child at Vietnam National Children’s Hospital: A case report. Ann Clin Anal Med 2025;16(Suppl 2):S124-127
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
The miliyer tuberculosis mimirating oropharynx carcinoma in a patient using anti-TNF: Review of the literature
Tuğba Kahraman Denizhan 1, Melih Kızıltepe 1, Hüseyin Kaplan 2, Emel Oğuz Kökoğlu 1, Celil Barlas Cengiz 1, Abdurrahman Soner Şenel 1
1 Department of Internal Medicine, 2 Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkiye
DOI: 10.4328/ACAM.22312 Received: 2024-06-24 Accepted: 2024-09-09 Published Online: 2024-12-30 Ann Clin Anal Med 2025;16(Suppl 2):S128-131
Corresponding Author: Tuğba Kahraman Denizhan, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkiye. E-mail: tugba_dr_@hotmail.com P: +90 555 617 53 83 Corresponding Author ORCID ID: https://orcid.org/0000-0001-7007-1160
Other Author ORCID ID: Melih Kızıltepe, https://orcid.org/0000-0001-6100-2024 . Hüseyin Kaplan, https://orcid.org/0000-0002-3292-0907 . Emel Oğuz Kökoğlu,https://orcid.org/0000-0002-5475-2182 . Celil Barlas Cengiz,https://orcid.org/0009-0002-6902-6017 . Abdurrahman Soner Şenel,https://orcid.org/ 0000-0001-9311-8179
Tumor necrosis factor-alpha (TNF-α) inhibitors are biological agents frequently used in many clinics, especially in rheumatology. In this article, we report a 59-year-old woman with RA who received adalimumab treatment for five years. The diagnosis and treatment of miliary tuberculosis secondary to irregular latent tuberculosis (TB) treatment with atypical symptoms will be discussed. In the literature, patients with a similar diagnosis who developed TB during treatment have also been presented. Patients at risk of latent TB who receive anti-TNF therapy should be closely monitored and the importance of prophylaxis should be emphasized.
Keywords: Anti-Tnf Treatment, Latent Tuberculosis, Miliary Tuberculosis
Introduction
With the introduction of tumor necrosis factor-alpha inhibitors (TNFAI) into clinical use, significant success has been achieved in treating many inflammatory diseases, especially rheumatoid arthritis (RA), seronegative spondyloarthropathy, and inflammatory bowel diseases. Unlike many other anti-inflammatory drugs, TNFAI acts through a targeted therapy mechanism. However, many remarkable side effects associated with these drugs are also reported. These; include mycobacterial infections, especially tuberculosis (TB), other viral, fungal, or bacterial infections, infusion reactions, local reactions at the injection site, heart failure, demyelinating diseases, triggering of autoimmunity, and malignancy [1].
Infliximab, a chimeric monoclonal antibody containing the murine Fab region; fully humanized monoclonal antibodies adalimumab and golimumab; certolizumab, a pegylated human Fab fragment, and etanercept, a fusion protein of the extracellular domain of Tumor necrosis factor receptor 2 (TNFR2) and the human immunoglobulin (Ig)1 Fc fragment, are TNF-α blockers approved for clinical use [2].
The risk of infection is thought to be higher, especially in the first year of treatment. It has been reported that the monoclonal antibodies adalimumab and infliximab are more prone to infections than the soluble receptor etanercept [3].
A meta-analysis summarizing the risk of TB associated with TNF-α blockade in thousands of patients with RA or other inflammatory diseases has shown an approximately four-fold increase in TB in those treated with TNF-α blockers compared with other treatments [4]. Here, we will talk about a case of miliary TB presenting with atypical symptoms such as sore throat and hoarseness, using adalimumab, a monoclonal antibody, with a diagnosis of RA.
In this article, we will discuss a case of TB associated with anti-TNF use and review similar cases in the literature.
Material and Methods
A 59-year-old female patient, diagnosed with seronegative RA for seven years, was started on adalimumab treatment five years previously after failing to respond to non-biologic disease-modifying anti-rheumatic drugs (DMARDs) and was in clinical remission for RA. Three years ago, after the patient’s PPD (purified protein derivative) test was 11 mm, the patient was started on isoniazid (INH). The patient used INH for three months, then took a two-month break due to coronavirus disease-2019 (COVID-19); and then continued for seven more
months. The treatment was completed in 9 months. When the patient developed complaints of sore throat and hoarseness three years after prophylaxis, acute upper respiratory tract infection was considered and antibiotic therapy was started. The patient, whose complaints did not improve, applied for a routine rheumatology check-up. In laboratory parameters; C-reactive protein: 4.62 mg/L (0-5), erythrocyte sedimentation rate: 53 mm/h (0-20), white blood cell count: 5.02×10³/µl, platelet count: 267×10³/µl, and hemoglobin: 13.1 g/dl. The patient attended the Department of Otolaryngology with the current complaints. Upon neck computed tomography (CT) showing a mass lesion measuring 26×14 mm in the oropharynx (figure 1A), a biopsy was planned with suspicion of malignancy in the oropharynx, and the biopsy result was reported as “granulomatous inflammatory event accompanied by focal ulceration.” Thorax CT was requested for the patient with the preliminary diagnosis of TB. In thorax CT, In the right axillary fossa, several enlarged lymph nodes, the largest of which was 9×12 mm, with thick cortex, whose fatty hilus could not be discerned, and LAPs, the largest of which was subcarinal and 20×30 mm in size, were observed in the mediastinum, in the prevascular area, in both upper paratracheal and lower right paratracheal areas, and in both hilar regions in the subcarinal area. In evaluating the lung parenchyma areas, more prominent widespread budded tree appearances were observed in the upper lobes of both lungs (active TB?)(figure 1B/ 1C).
Paramediastinal atelectatic density change was observed in the anterior upper lobe of the left lung. The patient’s transbronchial biopsy result was reported as a granulomatous inflammatory event by the chest diseases department, and quadruple anti-TB treatment was started after the lavage taken from the patient also showed Mycobacterium Tuberculosis growth. The patient was commenced on isoniazid, rifampicin (RIF), ethambutol, and pyrazinamide, and since she was not stable during follow-up, dual treatment with INH and RIF was started two months later. She is currently in the ninth month of her treatment, which is planned to be completed in 12 months. All radiological imaging studies and laboratory tests of the patient were performed at our institution.
A literature search with the keywords “adalimumab”, “rheumatoid arthritis” “tuberculosis”, and yielded 67 results in PUBMED and 40 results in SCOPUS over the last 10 years. When the results were screened, there were 15 RA patients who developed tuberculosis under adalimumab (Table 1).
Informed Consent: Written informed consent was obtained from the patients who participated in this study.
Results
When the results were screened, there were 15 RA patients who developed tuberculosis under adalimumab. Most of the cases were female patients. The mean age was 64 years, and the mean interval between adalimumab treatment and TB was 40.7 months. Similarly, TB was observed in our case 48 months after prophylaxis. Four miliary TB, 3 peritoneal TB, 4 pulmonary TB, 2 tongue TB, 1 brain TB, and 1 ganglionary TB were observed. As in our case, pulmonary TB is common in the literature. Seven patients had a negative TST or IGST, 3 had a positive TST or IGST, 2 did not receive prophylaxis and 5 did not report results.
Although TST or IGST was positive, miliary and atypical localized TB was observed in patients who did not receive prophylaxis. As in the literature and in our case, negative TST and IGST are insufficient to predict the development of TB.
Discussion
Rheumatoid arthritis is one of the most common chronic inflammatory diseases that can lead to bone and cartilage damage, as well as disability. TNFAI treatment has been established as an effective therapeutic strategy in patients with RA. TNF-α is a pro-inflammatory cytokine that plays a vital role in the pathogenesis of chronic immune-mediated diseases. Five TNFAIs have been approved for clinical use in rheumatology practice. These are infliximab, etanercept, adalimumab, certolizumab, and golimumab [5].
TNFAI drugs are generally well tolerated; However, many potentially serious adverse effects have also been reported. Long-term use of these drugs has been associated with the risk of malignancies and serious infections such as TB [6].
It is recommended to screen for latent TB infection before starting treatment in patients for whom TNFAI is planned. Although there is no gold standard test for this purpose, interferon-gamma release test (IGST) and tuberculin skin test (TST) can be used for screening purposes. If induration is ≥5 mm in TST, it is considered positive, and protective treatment is applied. It seems appropriate to screen patients for whom latent TB is not detected initially and TNFAI treatment is initiated annually for latent TB infection [7, 8]. Prophylaxis was started in our patient when the TST was 11 mm, and there was a disruption in his treatment due to COVID-19 infection. Therefore, her prophylaxis was negatively affected.
Cases of TB despite negative TST or IGST have been observed in the literature. Miliary or pulmonary TB is frequently seen, but atypical localisations are also noteworthy, although rare.
In conclusion, the risk of TB is increased in patients receiving TNFAI, especially infliximab and adalimumab. As seen in the literature, pulmonary and miliary TB are frequently observed. Screening for latent TB with TST or IGST before treatment should not be neglected as it reduces the risk of TB; however, even with a negative test result, patients should be closely monitored and informed. TB infection may present with atypical symptoms such as cough, fever, sore throat, weight loss, and hoarseness. Laboratory and imaging findings in patients with atypical presentations may initially cause diagnostic confusion. Therefore, in cases where the diagnosis is suspected, tissue biopsy may be helpful in the diagnosis if necessary.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Funding: None
Conflict of Interest
The authors declare that there is no conflict of interest.
References
1. Acar M, Sutcu M, Salman N, Somer A. The risk of tuberculosis and TNF-alpha Inhibitors. J Pediatr Inf 2017;11(2):82-6.
2. Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(Suppl 1):11-34.
3. Liao H, Zhong Z, Liu Z, Zou X. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20(2):161-68.
4. Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229-37.
5. He B, Li Y, Luo WW, Cheng X, Xiang HR, Zhang QZ, et al. The risk of adverse effects of TNF-α ınhibitors in patients with rheumatoid arthritis: A network meta-analysis. Front Immunol. 2022;13:814429.
6. Shivaji UN, Sharratt CL, Thomas T, Smith S, Iacucci M, Moran GW, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664–80.
7. Kaplan H, Şaş S, Şenköy E, Cengiz G, Demir H. A side effect of TNF inhibitors that should not be forgotten in the COVID-19 pandemic: pulmonary tuberculosis. J PMR Sci. 2022;25(3):386-89.
8. Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, et al. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Int J Rheum Dis. 2016;19(8):799-805.
9. Assante LR, Barra E, Bocchino M, Zuccarini G, Ferrara G, Sanduzzi A. Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab. Infez Med. 2014;22(2):144-48.
10. Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R. Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis. 2008;40(8):677-78.
11. Yonekura CL, Oliveira RDR, Titton DC, Ranza R, Ranzolin A, Hayata AL, et al. Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil. Rev Bras Reumatol. 2017;57:477-483.
12. Tanaka T, Sekine A, Tsunoda Y, Takoi H, Lin SY, Yatagai Y, et al. Central nervous system manifestations of tuberculosis-associated immune reconstitution inflammatory syndrome during adalimumab therapy: a case report and review of the literature. Intern Med. 2015;54(7):847-51.
13. Ikuta K, Ota Y, Kuroki S, Matsumoto Y, Senda E, Mukohara S, et al. Development of disseminated tuberculosis with intestinal involvement due to adalimumab administration despite latent tuberculosis treatment. Intern Med. 2020;59(6):849-53.
14. Dantes E, Tofolean DE, Fildan AP, Craciun L, Dumea E, Tofolean IT, et al. Lethal disseminated tuberculosis in patients under biological treatment–two clinical cases and a short review. J Int Med Res. 2018;46(7):2961-69.
15. Cerda OL, de Los Angeles Correa M, Granel A, Marcos AI, Giraldo C, Rillo O, et al. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy. Eur J Rheumatol. 2019;6(1):19.
16. Chiesa Estomba CM, Araujo da Costa AS, Schmitz TR, Lago PV. Base of tongue tuberculosis: a case report. Iran J Otorhinolaryngol. 2015;27(80):239.
17. Muñoz-Oca JE, Villarreal Morales ML, Nieves-Rodriguez A, Martínez-Bonilla L. Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report. BMC Infect Dis. 2017;17:1-4.
18. Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, et al. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One. 2015;10(3).
19. Kim YJ, Kim YG, Shim TS, Koo BS, Hong S, Lee CK, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014;53(8):1477-81.
Download attachments: 10.4328.ACAM.22312
Tuğba Kahraman Denizhan, Melih Kızıltepe, Hüseyin Kaplan, Emel Oğuz Kökoğlu, Celil Barlas Cengiz, Abdurrahman Soner Şenel. The miliyer tuberculosis mimirating oropharynx carcinoma in a patient using anti-tnf: Review of the literature. Ann Clin Anal Med 2025;16(Suppl 2):S128-131
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Sarcopenia: A review of risk factors, diagnosis, and treatment methods
Abdullah Ozdemir 1, Asiye Ozdemir 2
1 Department of Anesthesiology and Reanimation, Ministry of Health Kanuni Education and Research Hospital, 2 Department of Intensive Care, Ministry of Health Kanuni Education and Research Hospital, Trabzon, Turkey
DOI: 10.4328/ACAM.22426 Received: 2024-09-27 Accepted: 2024-11-11 Published Online: 2024-12-11 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2):S132-136
Corresponding Author: Abdullah Ozdemir, Department of Anesthesiology and Reanimation, Ministry of Health Kanuni Education and Research Hospital, Trabzon, Turkey. E-mail: Abdullah.1565@gmail.com P: +90 505 217 41 67 Corresponding Author ORCID ID: https://orcid.org/0000-0002-4778-9622
Other Author ORCID ID: Asiye Ozdemir, https://orcid.org/0000-0002-7233-8380
Sarcopenia is a geriatric syndrome characterized by not only the loss of muscle mass but also the deterioration of muscle function. Risk factors include advanced age, male gender, lifestyle, increased body fat mass, smoking, diabetes, and malignancies. For diagnosis, the SARC-F questionnaire (Strength, Assistance with walking, rising from a chair, climbing stairs, and Falls) is recommended for assessing specific symptoms of sarcopenia. Numerous studies have shown that sarcopenia is associated with various adverse health outcomes, such as functional decline, increased healthcare costs, falls, fractures, hospital admissions increase, longer hospital stays, and higher mortality rates in older adults due to loss of muscle strength. Since the etiology of sarcopenia is multifactorial, its treatment and management of sarcopenic patients are also multifactorial. We believe that further studies are needed due to the clinical importance of sarcopenia.
Keywords: Sarcopenia, Elderly Individuals, Muscle Function Limitation
Introduction
Sarcopenia is a geriatric syndrome characterized by not only the loss of muscle mass but also the deterioration of muscle function. Sarcopenia is associated with various adverse health outcomes, including prolonged hospital stays, metabolic/cognitive disorders, and an increased risk of falls and fractures [1]. The word “sarcopenia” is derived from the Greek roots “sarx,” meaning flesh, and “penia,” meaning loss. It was first proposed by Rosenberg in 1989 to describe age-related loss of muscle mass. In the 1970s, it was referred to as losses in lean body mass associated with aging [2,3]. In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) published a definition of sarcopenia aimed at advancing the identification and care of individuals with sarcopenia. In early 2018, they reconvened to update the original definition. To confirm the diagnosis of sarcopenia, the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) has employed the detection of low muscle mass and quality, in addition to low muscle strength, which is one of the key characteristics of sarcopenia. Poor physical performance is identified as an indicator of severe sarcopenia [4]. In this review, we aimed to summarize the epidemiological characteristics, risk factors, and management of sarcopenia.
Epidemiology
Differences in sarcopenia outcomes can be observed between the general population and patients. This is likely due to both the demographic variations of the study groups and the differences in study outcomes, which should be taken into consideration. The presence of heterogeneity between studies, the use of small sample sizes, and potential errors in anthropometric measurements may render certain relationships inconclusive and could make the results open to debate. The factors mentioned above explain the differing results encountered in studies related to sarcopenia [1]. Moreover, variations in definitions used in studies on sarcopenia prevalence have led to differing outcomes. For instance, the prevalence of sarcopenia varies between definitions, with estimates ranging from 5% based on the EWGSOP1 criteria to 17% according to the International Working Group on Sarcopenia (IWGS). According to the Asian Working Group for Sarcopenia (AWGS), the prevalence of sarcopenia is around 8%. In a study conducted in our country, the general prevalence of sarcopenia in individuals aged 65 and older was found to be 5.2% (4.1% in women and 6.7% in men) [5, 6].
Risk Factors
There are numerous studies addressing the risk factors for sarcopenia. There is a relationship between sarcopenia and demographic factors such as age and gender. As age increases, the incidence of sarcopenia also rises. Additionally, in males, the rate of muscle loss and the incidence of sarcopenia increases with age [7].
The relationship between body mass index (BMI) and sarcopenia may appear complex. There is a positive correlation between the increase in body fat mass, rather than muscle mass, and sarcopenia [8].
Lifestyle, diet, and physical activity appear to be associated with sarcopenia. Sarcopenia may develop as a result of insufficient energy or protein intake, which can be attributed to factors such as anorexia, malabsorption, limited access to healthy foods, or impaired ability to eat [4].
Smoking has been associated with an increased risk of sarcopenia in a meta-analysis of 29 studies. Excessive alcohol consumption impairs skeletal muscle protein synthesis, and the exposure of muscle tissue to ethanol leads to autophagy, contributing to the development of sarcopenia. Additionally, there is a positive relationship between both short and long sleep durations and sarcopenia [8,9].
Diabetes and its complications are not only associated with risk factors for sarcopenia but also with the complications arising from sarcopenia. Other comorbidities, such as heart diseases, cognitive impairments, respiratory diseases, depression, and anorexia, have also been positively associated with an increased risk of sarcopenia [9, 10].
Sarcopenia is also significantly associated with a poorer prognosis in digestive system cancers, head and neck cancers, lung cancers, urothelial cancers, hematological malignancies, breast cancers, and ovarian cancers [11].
Early sarcopenia is characterized by a reduction in muscle size. Over time, a decline in muscle tissue quality also occurs. This is characterized by the replacement of muscle fibers with fat, increased fibrosis, alterations in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction. This ultimately leads to a progressive loss of muscle function and increased frailty [12].
There are several mechanisms that may be involved in the onset and progression of sarcopenia (Figure 1).
Histological changes in muscle fibers reveal that sarcopenia predominantly affects type II (fast-twitch) muscle fibers, while type I (slow-twitch) fibers are much less affected. It has been reported that there is a reduction in both the number and size of type II fibers [13].
Sarcopenia is classified into primary and secondary types based on its formation. While primary sarcopenia occurs due to old age, secondary sarcopenia occurs due to more than one cause. Unbalanced nutrition, decreased anabolic hormone levels, motor-neuron diseases, immobilization, apoptosis, and mitochondrial dysfunctions play a role in the formation of secondary sarcopenia [7].
According to EWGSOP2, sarcopenia consists of 3 stages
1-Probable sarcopenia: low muscle strength only
2-Confirmed sarcopenia: Low muscle strength + low muscle mass/quality
3-Severe sarcopenia: Low muscle strength + low muscle mass/quality + low physical performance [4]. Sarcopenic obesity Changes in body composition occur with aging. Both the loss of skeletal muscle mass and the increase in adipose tissue are common characteristics observed with aging. The combination of these two conditions, known as sarcopenic obesity, increases the risk of adverse health outcomes. The prognosis is worse in the patient group with chronic disease along with sarcopenic obesity. The prolonged treatment process for this patient group also increases hospital costs. In addition, anthropometric measurements used in the diagnosis of sarcopenic obesity may yield incorrect results. Therefore, imaging modalities hold greater importance in this patient group [14]. There is a significant overlap between frailty and sarcopenia; most frail older adults have sarcopenia Frailty is a geriatric syndrome. Frailty is characterized by unwanted weight loss, fatigue, weakness, slow walking speed, and low physical activity. It is characterized by deterioration of the homeostatic reserve and decreased resistance capacity of the organism to stress. Frailty involves increased sensitivity to adverse health outcomes such as hospitalization, institutional care, and death [15, 16].
Diagnosis and Evaluation Methods
The 2018 European Sarcopenia Guidelines (EWGSOP2) recommend the use of the SARC-F questionnaire (Strength, Assistance with walking, rising from a chair, climbing stairs, and Falls) to assess specific symptoms of sarcopenia. SARC-F can be used as a screening test that is easily applicable in community healthcare services and other clinical settings. SARC-F is a 5-item questionnaire self-reported by patients to screen for the risk of sarcopenia. The responses are based on the patient’s perception of their limitations in strength, walking ability, ability to rise from a chair, climbing stairs, and experiences with falls[4]. A score of 4 or above on the SARC-F questionnaire is considered significant for diagnosing sarcopenia (Table 1).
Muscle Strength
The handgrip test, also known as hand dynamometry, is used to provide a quantitative measure of muscle strength. Separate reference values are available for males and females in this test. In males, the handgrip strength should be 27 kg or higher, and in females, it should be 16 kg or higher. If the values fall below these thresholds, the individual is considered to have a lack of muscle strength, indicating possible sarcopenia [4]. Techniques such as knee flexion and extension, as well as peak expiratory flow methods, can also be used for the assessment of muscle strength. However, these two methods have disadvantages in terms of clinical applicability [7].
Muscle Mass Measurement
Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are considered the gold standards for the non-invasive assessment of muscle mass/quantity. However, these tools have several disadvantages, including high equipment costs, lack of portability, the need for highly trained personnel to operate the equipment, and increased overall costs. Additionally, the radiation exposure associated with CT scans has introduced limitations to its widespread use as a first-line diagnostic tool [4]. Dual-energy X-ray absorptiometry (DEXA) is a more commonly used tool for non-invasive measurement of muscle mass, such as total body lean tissue mass DEXA measurements may be affected by the patient’s hydration status. The patient’s hydration status should be considered before conducting measurements. Additionally, there is a direct correlation between an increase in height and muscle mass. Both skeletal muscle mass (SMM) and appendicular muscle mass (ASM) can be measured. Appendicular Skeletal Muscle (ASM) mass of 15 kg or more in women and 20 kg or more in men is considered normal. Another method used in the diagnosis of sarcopenia is the skeletal muscle mass index (SMI, skeletal muscle mass index, ASM/Ht2 (kg/m2), which is obtained by dividing SMM or ASM values by height squared. For ASMI, normal values are 7 kg/m2 or higher in men and 5.5 kg/m²2 or higher in women [4,18]. Both skeletal muscle mass (SMM) and appendicular muscle mass (ASM) can be measured with Bioelectrical Impedance Analysis (BIA). BIA equipment does not directly measure muscle mass but instead derives a muscle mass estimate based on whole-body electrical conductivity. It operates based on the principle of quantifying the body’s resistance to harmless alternating electrical currents sent through the body. BIA equipment, particularly single-frequency devices, is affordable, widely available, and portable. In addition, BIA measurements may also be affected by the patient’s hydration status [4]. A definitive diagnosis of sarcopenia is made when both low muscle strength and low muscle mass are observed.
Anthropometric measurements are also used to estimate muscle mass. For this purpose, measurements of mid-upper arm circumference, skinfold thickness, and calf circumference can be performed. There is a positive correlation between calf thickness and muscle mass. One of the disadvantages of anthropometric measurements is the difficulty in obtaining accurate readings due to fat deposits and loss of skin elasticity that can occur with aging. On the other hand, due to the variability in measurements depending on the person performing them, anthropometric measurements are not recommended for routine diagnosis of sarcopenia on their own. However, it is suggested that they be combined with other tests for a more comprehensive evaluation [4, 19].
Physical Activity Evaluation
Physical performance assesses whole-body function, which is objectively measured in relation to movement. It is described as multidimensional, involving not only muscles but also many functions, including balance. Physical performance can be measured in a variety of ways, including gait speed, Short Physical Performance Battery (SPPB), and Timed-up and-go (TUG), among other tests. It may not always be possible to assess a patient’s test performance. For example, this may not be possible for patients with dementia, Parkinson’s, or gait deformity.
The walking speed of a person with normal muscle functions should be above 0.8 m/s. In the TUG test, the individual is asked to rise from a seated position without using their arms, walk 3 meters at a normal pace, turn around, and return to sit in the same spot. It is recorded in how many seconds the patient completes the specified activity. This time should normally be less than 20 seconds [4].
Stair Climbing Power Test: Primarily used for research purposes, this test involves asking the patient to step up and down on a platform of a certain height, with the time taken being compared to standard reference values [19].
When both muscle strength and mass are found to be low, and physical activity is also reduced, this condition is referred to as severe sarcopenia.
Alternative or new tests
The methods discussed here are used to assess muscle quantity and quality and their impact on the patient’s quality of life. These diagnostic measurements are tested for validity, reliability, and accuracy, and they may play a significant role in the future. Factors such as cost, effectiveness, and standardization should be considered when using these methods.
Lumbar 3rd vertebra imaging with computed tomography
CT is considered the gold standard method for determining body composition because it distinguishes between fat and other soft tissues, has a strong correlation with total body muscle mass and fat mass, and provides a way to measure the cross-sectional area of tissue at the L3 vertebral level [20].
Specifically, CT images at a particular lumbar vertebral level (L3) have shown a significant correlation with total body muscle mass. This imaging method has been used to detect low muscle mass, even in patients with normal or high body weight. It can also be used to predict the prognosis of these patients [20]. It plays an important role in measuring muscle mass and detecting sarcopenia in the early stages [4, 21].
Mid-thigh muscle measurement
Mid-thigh imaging (with MRI or CT) has also been used in research studies. It is a good predictor of whole-body skeletal muscle mass. The mid-thigh muscle area is more strongly correlated with total body muscle volume compared to the L1–L5 lumbar muscle areas [21].
Psoas muscle measurement by computed tomography
Measurement of the psoas muscle with CT has also been used as a morbidity predictor in some studies, especially in conditions such as cirrhosis and colorectal surgery. However, since the psoas is a small muscle, some experts suggest that there are question marks about its use in the definition of sarcopenia. Further studies are needed to confirm or deny the reliability of this method [4].
Ultrasound Assessment of Muscle
Ultrasound is a non-invasive, radiation-free method with advantages such as bedside applicability by reliable and trained clinicians. It can be widely used to measure the amount of muscle, determine muscle loss, and also measure muscle quality. Assessment of pennate muscles, such as the quadriceps femoris, may detect a decrease in muscle thickness and cross-sectional area in a relatively short period of time [22].
Creatine dilution test
Creatine is produced by the liver and kidneys and is also obtained through a diet rich in meat. Creatine is taken up by muscle cells as phosphocreatine, converted into creatinine, and excreted in the urine. The rate of creatinine excretion is promising for estimating total body muscle mass. Total body creatine pool size and muscle mass are calculated from the enrichment of D3-creatinine in the urine. Creatine dilution test results show a strong correlation with MRI-based measurements of muscle mass and a moderate correlation with BIA and DEXA measurements. The creatine dilution test is currently primarily used in research settings, making its application in clinical environments impractical [23].
Specific Biomarkers
The development of a single biomarker could provide an easy and cost-effective means to diagnose individuals with sarcopenia and monitor treatment progress. However, due to the multifactorial pathophysiology of sarcopenia, it is currently not feasible to identify a single biomarker that can accurately characterize this condition across a heterogeneous population [20] Identifying a biomarker for sarcopenia would represent a significant advancement for diagnosis, treatment, and prognosis.
Outcomes and Complications of Sarcopenia
Numerous studies have demonstrated that sarcopenia is associated with various adverse health outcomes, including functional decline, loss of muscle strength, disability, healthcare costs, falls, fractures, increase in repeat hospitalizations, prolonged hospital stays, and increased mortality rates among older adults [9].
Sarcopenia is an increasingly prevalent global public health issue. It has been reported that sarcopenia affects 5-13% of individuals over 60 years old and 50% of those over 80 years old. In 2004, the total cost of sarcopenia to the American healthcare system was estimated to be approximately $18.4 billion [24]. In 2000, it was estimated that there were 600 million individuals aged 60 and above worldwide. This population is expected to rise to 1.2 billion by 2025 and 2 billion by 2050. This means that the elderly population is steadily increasing. With a more restrictive estimate, sarcopenia currently affects over 50 million people and could impact over 200 million individuals in the next 40 years [16].
Treatment and Management Strategies
Because the etiology of sarcopenia is multifactorial, its treatment and management of sarcopenic patients are also multifaceted. Early diagnosis and prompt initiation of treatment are of utmost importance. To manage sarcopenia, a multidisciplinary approach involving clinicians, physiotherapists, and dietitians is essential. The treatment can be divided into non-pharmacological and pharmacological approaches.
Non-pharmacological Approaches
Physical inactivity is directly associated with the loss of muscle strength and mass. One of the cornerstones of sarcopenia treatment is exercise under the guidance of a specialist. Short-term resistance exercise has been demonstrated to enhance the skeletal muscle’s ability and capacity for protein synthesis. Both resistance training and strength training have been shown to be effective interventions in the prevention and treatment of sarcopenia [2, 25].
Pharmacological Approaches
There are no agents approved by the Food and Drug Administration (FDA) for the treatment of sarcopenia in the United States. Dehydroepiandrosterone (DHEA) and human growth hormone have very limited effects. Growth hormone enhances muscle protein synthesis and increases muscle mass; however, it does not lead to significant gains in strength and function [26].
Testosterone and other anabolic steroids have positive effects on muscle strength and mass. However, their use is limited due to the increased risk of prostate cancer in men, virilization in women, and cardiovascular side effects [16, 26].
Among the compounds researched for sarcopenia treatment are myostatin inhibitors, vitamin D, angiotensin-converting enzyme inhibitors, eicosapentaenoic acid, thalidomide, OHR/AVR118, celecoxib, VT-122, omega-3 supplements, and anabolic agents such as ghrelin and its analogs, MT-102, BYM338, and ruxolitinib [16].
There is considerable interest in using herbal supplements to improve muscle mass and function in patients with sarcopenia. Some herbal compounds have shown positive effects on skeletal muscles in human studies. These include curcumin derived from Curcuma longa, alkaloids and steroidal lactones obtained from Withaniasomnifera (Solanaceae), catechins derived from Camellia sinensis, proanthocyanidins from grape seeds, and gingerols and shogaols derived from Zingiber officinale [27].
In the treatment of malnutrition-related sarcopenia, similar nutritional plans to those used for cachectic patients should be implemented. A daily protein intake of 1.2 to 1.6 g/kg/day is recommended to prevent age-related sarcopenia [28].
Conclusion
Sarcopenia is a significant health issue that negatively affects the quality of life and limits independence in the elderly population. Although progress has been made in the diagnosis and treatment of this condition, which requires a multidisciplinary approach, there are still important steps to be taken. Further clarification of diagnostic criteria and treatment approaches, development of personalized treatment strategies, and increasing awareness are crucial. Future scientific studies will contribute to the creation of more effective and comprehensive approaches to combating sarcopenia. This review aims to raise awareness of sarcopenia and support more effective management of this important geriatric problem in clinical practice.
Scientific Responsibility Statement
The authors declare that they are responsible for the article’s scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.
Animal and human rights statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or compareable ethical standards.
Funding: None
Conflict of Interest
The authors declare that there is no conflict of interest.
References
1. Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023;144:155533.
2. Tezze C, Sandri M, Tessari P. Anabolic resistance in the pathogenesis of sarcopenia in the elderly: Role of nutrition and exercise in young and old people. Nutrients. 2023;15(18):4073.
3. Bautmans I, Van Puyvelde K, Mets T. Sarcopenia and functional decline: pathophysiology, prevention and therapy. Acta Clin Belg. 2009;64(4):303-16.
4. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
5. Carvalho Do Nascimento PR, Bilodeau M, Poitras S. How do we define and measure sarcopenia? A meta-analysis of observational studies. Age Ageing. 2021;50(6):1906-13.
6. Simsek H, Meseri R, Sahin S, Kilavuz A, Bicakli DH, Uyar M, et al. Prevalence of sarcopenia and related factors in community-dwelling elderly individuals. Saudi Med J. 2019;40(6):568-74.
7. Ozkaya Sağlam B, Küçükgüçlü O. Yaşlılarda Sarkopeni ve Hemşirelik [Sarcopenia in Older Adults and Nursing]. Dokuz Eylül Üniversitesi Hemşire Fakültesi Elektron Derg. 2021;14(4):461-70.
8. Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis. J Clin Endocrinol Metab. 2022;107(5):1470-83.
9. Gao Q, Hu K, Yan C, Zhao B, Mei F, Chen F, et al. Associated Factors of Sarcopenia in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. Nutrients. 2021;13(12):4291.
10. Li Z, Tong X, Ma Y, Bao T, Yue J. Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and meta‐analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):128-44.
11. Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, et al. Sarcopenia and adverse health‐related outcomes: An umbrella review of meta‐analyses of observational studies. Cancer Med. 2020;9(21):7964-78.
12. Ryall JG, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology. 2008;9(4):213-28.
13. Doherty TJ. Invited Review: Aging and sarcopenia. J Appl Physiol. 2003;95(4):1717-27.
14. Tieland M, Van Dronkelaar C, Boirie Y. Sarcopenic obesity in the ICU. Curr Opin Clin Nutr Metab Care. 2019;22(2):162-66.
15. Bauer JM, Kaiser MJ, Sieber CC. Sarcopenia in Nursing Home Residents. J Am Med Dir Assoc. 2008;9(8):545-51.
16. Dhillon RJS, Hasni S. Pathogenesis and management of sarcopenia. Clin Geriatr Med. 2017;33(1):17-26.
17. Malmstrom TK, Morley JE. SARC-F: A simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531-32.
18. Moon JJ, Park SG, Ryu SM, Park CH. New skeletal muscle mass index in diagnosis of sarcopenia. J Bone Metab. 2018;25(1):15.
19. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412-23.
20. Tosato M, Marzetti E, Cesari M, Savera G, Miller RR, Bernabei R, et al. Measurement of muscle mass in sarcopenia: From imaging to biochemical markers. Aging Clin Exp Res. 2017;29(1):19-27.
21. Schweitzer L, Geisler C, Pourhassan M, Braun W, Glüer CC, Bosy-Westphal A, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? Am J Clin Nutr. 2015;102(1):58-65.
22. Galindo Martín CA, Monares Zepeda E, Lescas Méndez OA. Bedside Ultrasound Measurement of Rectus Femoris: A Tutorial for the Nutrition Support Clinician. J Nutr Metab. 2017;2017:1-5.
23. Clark RV, Walker AC, Miller RR, O’Connor-Semmes RL, Ravussin E, Cefalu WT. Creatine ( methyl -d 3 ) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. J Appl Physiol. 2018;124(1):1-9.
24. Morley JE. Sarcopenia: Diagnosis and treatment. J Nutr Health Aging. 2008;12(7):452-56.
25. Yarasheski KE. Review Article: exercise, aging, and muscle protein metabolism. J Gerontol A Biol Sci Med Sci. 2003;58(10):M918-M922.
26. Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol. 2012;2012:1-10.
27. Rondanelli M, Miccono A, Peroni G, Guerriero F, Morazzoni P, Riva A, et al. A systematic review on the effects of botanicals on skeletal muscle health in order to prevent sarcopenia. Evid Based Complement Alternat Med. 2016;2016(1):5970367.
28. Phillips SM, Chevalier S, Leidy HJ. Protein “requirements” beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab. 2016;41(5):565-72.
Download attachments: 10.4328.ACAM.22426
Abdullah Ozdemir, Asiye Ozdemir. Sarcopenia: A review of risk factors, diagnosis, and treatment methods. Ann Clin Anal Med 2025;16(Suppl 2):S132-136
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Arachnoid cyst in a patient with chronic kidney disease: Is it always innocent?
Esra Geçgel 1, Alper Alp 2, Dilek Gibyeli Genek 2, Bülent Huddam 2
1 Department of Internal Medicine, 2 Department of Nephrology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey
DOI: 10.4328/ACAM.22361 Received: 2024-08-09 Accepted: 2024-12-24 Published Online: 2025-01-31 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22361
Corresponding Author: Alper Alp, Department of Nephrology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. E-mail: alperalp@mu.edu.tr P: +90 530 310 22 44 Corresponding Author ORCID ID: https://orcid.org/0000-0002-2864-361X
Other Authors ORCID ID: Esra Geçgel, https://orcid.org/0009-0009-7324-2311 . Dilek Gibyeli Genek, https://orcid.org/0000-0001-6104-5577 . Bülent Huddam, https://orcid.org/0000-0002-8412-1584
To the editor:
A 51-year-old male was hospitalized due to incidentally detected deterioration in renal function tests. He had hyperlipidemia and hypertension without a history of cranial trauma/seizures. Also, a family history of seizures was absent. Renal ultrasonography revealed bilateral atrophic kidneys with an echogenicity grade 3. In the fundus examination of the patient with congenital left eye exotropia to investigate hypertensive retinopathy, atrophy of the optic disc of the left eye was detected along with fundus findings consistent with bilateral grade 2 hypertensive retinopathy. Further examination was recommended due to suspicion of compression secondary to the intracranial lesion. Meanwhile, the patient developed temporary syncope after hemodialysis but refused treatment and left the hospital. The patient, who presented to the emergency department with uremic findings 2 months later, was taken to emergency hemodialysis upon detection of urea: 200 mg/dl, creatinine 9.5 mg/dl. An arachnoid cyst (AC) was detected in non-contrast cranial CT and cranial magnetic resonance imaging [Figure 1, 2]. Neurosurgically, it was evaluated as congenital type 3 AC, and urgent intervention was not considered. The patient, who continued on the 3/7 hemodialysis program, applied to the emergency department 4 months later with a complaint of right focal tonic contraction that occurred suddenly before the hemodialysis session and lasted longer than 5 minutes. The eyes were open spontaneously, the patient was non-cooperative, the light reflex was +/+, the right eye deviated outwards while the eyes were in a neutral position (sequela sign), and there were tonic contractions in 4 extremities. He was intubated and admitted to intensive care due to status epilepticus. He was followed up with midazolam and levetiracetam treatment and was discharged when his neurological condition improved.
ACs constitute 1% of benign, non-traumatic intracranial lesions [1]. It can be congenital (mostly) or familial [2]. Approximately half of these cysts are located in the middle cranial fossa. In cyst pathophysiogenesis, hypotheses such as abnormalities occurring in the separation or duplication of the arachnoid membrane during embryological life, the osmotic pressure difference between the arachnoid cyst/space, the presence of Aquaporin 1 receptors in the cyst membrane, and the accumulation of cerebrospinal fluid (CSF) between the arachnoid membrane leaves have been put forward. It is usually asymptomatic, but over time, it may become symptomatic with the increase in CSF accumulated in the cyst, resulting in cyst expansion. Neurological symptoms due to arachnoid cysts are observed in only 5% of the patients. In a study in which patients with focal epilepsy were evaluated retrospectively, the presence of AC was found to be higher than in healthy volunteers [3]. However, Brutto et al. could not find a significant relationship between supratentorial ACs and seizures or epilepsy [4]. AC can serve as a basis for very serious clinical conditions such as status epilepticus, as in our patients. The determinant in the AC clinic is usually mass compression, and the increase in intracystic fluid due to cyst membrane fragility and rupture caused by micro or macro cranial traumas may potentiate this effect.
Although they are mostly considered ‘’benign’’ in general population studies, incidentally detected ACs in CKD cases-especially large ones, should be followed closely, and it should be kept in mind that they may cause serious clinical problems in this population, which is already at high risk for seizures.
References
1. Sharma R, Gupta P, Mahajan M, Sharma P, Gupta A, Khurana A. Giant nontraumatic intradiploic arachnoid cyst in a young male. Radiol Bras. 2016;49(5):337-9.
2. Stanishevskiy A, Gizatullin S, Davydov D. Giant arachnoid cyst in adult presented with secondary epileptiform activity. Surg Neurol Int. 2021;12:418.
3. Nikolić I, Ristić A, Vojvodić N, Baščarević V, Ilanković A, Berisavac I, et al. The association of arachnoid cysts and focal epilepsy: hospital-based case control study. Clin Neurol Neurosurg. 2017;159:39-41.
4. Del Brutto OH, Mera RM, Kiernan J, Castle P, Zambrano M, Sedler MJ. Supratentorial arachnoid cysts and seizures/epilepsy: A population study in community dwellers aged ≥20 years. Epilepsia. 2019;60(8):e83-e87.
Download attachments: 10.4328.ACAM.22361
Alper Alp. Arachnoid cyst in a patient with chronic kidney disease: Is it always innocent? Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22361
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
The assessment of computational intelligence technique for the diagnosis of acute lymphoblastic leukemia
Fatma Yılmaz 1, Guner Kılıc 2
1 Department of Hematology, 2 Department of Gastroenterology, Ankara Etlik City Hospital, Ankara, Turkey
DOI: 10.4328/ACAM.22471 Received: 2024-10-31 Accepted: 2024-12-02 Published Online: 2025-01-14 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22471
Corresponding Author: Fatma Yılmaz, Department of Hematology, Ankara Etlik City Hospital, Ankara, Turkey. E-mail: dr.fatmak@hotmail.com P: +90 506 882 38 69 Corresponding Author ORCID ID: https://orcid.org/0000-0001-6112-3950
Other Author ORCID ID: Guner Kilic, https://orcid.org/0000-0001-6799-3391
To the editor:
Artificial intelligence, first defined by McCarthy in 1956, is defined as the science in which technology is used to simulate human-like behavior and reasoning ability [1]. Studies on the use of artificial intelligence applications in the field of medicine are increasing day by day. There are also studies in the literature on the possible contributions of artificial intelligence use in the field of hematology, especially in the diagnosis phase. Leukemias are mainly divided into two groups in hematology: acute and chronic leukemias. Acute leukemias are characterized by more than 20% blasts in the blood or bone marrow blood. Acute leukemias can be classified as myeloid (AML) and lymphoid (ALL) based on the cell type from which they originate. Acute lymphoblastic leukemia (ALL): Since it has a high mortality rate and is highly treatable when diagnosed early, being quick in diagnosis is an important point. Although technologies such as flow cytometric methods are used in diagnosis, definitive diagnosis is still based on microscopic examination. There are articles in the literature on artificial intelligence applications in ALL diagnoses. Alaoui et al. reported that artificial intelligence was used for ALL diagnoses with a database created using patients’ complete blood count, and a high accuracy rate (91.4%) was achieved [2]. Rizayi et al. reported that artificial intelligence was used for ALL diagnoses with a database created using patients’ peripheral smear images [3]. Shafique et al. showed that in 2018, artificial intelligence systems were used for both automatic ALL diagnosis and determination of its subtypes (L1, L2, and L3) [4]. If artificial intelligence applications will be used at the time of diagnosis, especially in hematological malignancies where definitive diagnosis with microscopy is still the gold standard, the data to be used should not be only microscopic images or only complete blood count results. In addition to both microscopic images and complete blood counts, studies are needed with artificial intelligence versions that will be developed by including patient gender, nationality, and patient health status diversity. In artificial intelligence applications used for diagnosis, an infrastructure that not only allows for general ALL diagnosis but also for determining its subtypes may be more useful. Artificial intelligence can be used to support doctors in the triage process, to reduce the number of unnecessary referrals to hematology clinics in tertiary hospitals, and to provide rapid and adequate intervention for ALL suspected cases that require advanced examination. After the ALL diagnosis, artificial intelligence can make a significant contribution to clinicians in planning patient-based treatment, and studies on this subject are needed.
References
1. Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. J Fam Med Prim Care. 2019;8(7):2328-31.
2. El Alaoui Y, Padmanabhan R, Elomri A, Qaraqe MK, El Omri H, Yasin Taha R. An artificial intelligence-based diagnostic system for acute lymphoblastic leukemia detection. In: Healthcare Transformation with Informatics and Artificial Intelligence: IOS Press; 2023.p.265-68.
3. Rezayi S, Mohammadzadeh N, Bouraghi H, Saeedi S, Mohammadpour A. Timely diagnosis of acute lymphoblastic leukemia using artificial intelligence‐oriented deep learning methods. Computl Intell Neurosci. 2021;2021(1):1-12.
4. Shafique S, Tehsin S. Acute lymphoblastic leukemia detection and classification of its subtypes using pretrained deep convolutional neural networks. Technol Cancer Res Treat. 2018;17(1):1-7.
Download attachments: 10.4328.ACAM.22471
Fatma Yılmaz. The assessment of computational intelligence technique for the diagnosis of acute lymphoblastic leukemia. Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22471
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
Can artificial intelligence contribute to non-alcoholic fatty liver disease monitoring?
Guner Kilic
Department of Gastroenterology, Ankara Etlik City Hospital, Ankara, Turkey
DOI: 10.4328/ACAM.22478 Received: 2024-11-04 Accepted: 2024-12-09 Published Online: 2025-01-06 Printed: 2025-05-25 Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22478
Corresponding Author: Guner Kilic, Department of Gastroenterology, Ankara Etlik City Hospital, Ankara, Turkey. E-mail: gunerrkilic@gmail.com P: +90 532 316 84 21 Corresponding Author ORCID ID: https://orcid.org/0000-0001-6799-3391
To the editor:
Non-alcoholic fatty liver disease (NAFLD) is one of an increasing number of liver diseases that encompass a wide spectrum from steatohepatitis to cirrhosis. Liver fibrosis is characterized by progressive accumulation of connective tissue accompanied by necroinflammation and ballooning and is one of the main prognostic factors in NAFLD [1]. The gold standard method to assess liver fibrosis is liver biopsy. Since liver biopsy is invasive and not easy to use in routine daily clinical practice, researchers have turned to non-invasive tests that are easy to use and perform well. Non-invasive tests are generally divided into two main groups: serum tests and imaging methods. In the literature, there are studies in the prediction of fibrosis in NASH patients with serum tests and scores such as Fibrosis-4 Index (FIB-4), Aspartate Aminotransferase Platelet Ratio Index (APRI), BARD score, NAFLD fibrosis score [2].
Ultrasonography (USG) elastography and Magnetic Resonance (MR) elastography are non-invasive imaging modalities to evaluate liver fibrosis. Although fibroscan is currently considered the most valid method, MR elastography is more effective in panoramic evaluation of the liver and intermediate-stage classification [3].
Because of the risk of transformation of NAFLD into liver cirrhosis and hepatocellular carcinoma, close monitoring of the disease and early intervention in its progression is of great importance. Artificial intelligence, first defined in 1956, is a technological substructure that uses computer systems that can mimic human-like cognitive functions such as learning and problem-solving. Zamanian et al. 2024 summarized artificial intelligence-assisted diagnostic models used in the prognosis of NAFLD. They reported that artificial intelligence models using USG-based imaging methods and clinical data together achieved high-reliability percentages in detecting NAFLD prognosis and possible complications[4]. Data-based artificial intelligence applications created by synthesizing imaging methods, serum tests, serum scores, retrospective liver biopsy microscopic images, and patient demographic characteristics will be guiding for multifaceted diseases such as NAFLD, whose prognosis is difficult to predict in advance. With the introduction of such artificial intelligence-based applications into routine clinical practice, benefits such as accelerating disease diagnosis, obtaining early information in prognosis prediction, and reducing possible treatment costs can be achieved. Broad-based studies with large numbers of patients are needed before they can enter routine clinical practice.
References
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
2. Arulanandan A, Loomba R. Noninvasive testing for NASH and NASH with advanced fibrosis: are we there yet? Curr Hepatol Rep. 2015;14(2):109-118.
3. Shipley LC, Axley PD, Singal AK. Liver fibrosis: A clinical update. EMJ Hepatology. 2019;7(1):105-17.
4. Zamanian H, Shalbaf A, Zali MR, Khalaj AR, Dehghan P, Tabesh M, et al. Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: a systematic review (2005–2023). Comput Methods Programs Biomed. 2024;244:107932.
Download attachments: 10.4328.ACAM.22478
Guner Kilic. Can artificial intelligence contribute to non-alcoholic fatty liver disease monitoring? Ann Clin Anal Med 2025;16(Suppl 2): DOI: 10.4328/ACAM.22478
Citations in Google Scholar: Google Scholar
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/